var title_f9_28_9664="Cat scratch disease PI";
var content_f9_28_9664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cat scratch disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cat scratch disease causes redness, swelling, and small round bumps at the site of the bite or scratch, as shown on this finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9664=[""].join("\n");
var outline_f9_28_9664=null;
var title_f9_28_9665="Central lung tumor PET";
var content_f9_28_9665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Central bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two coronal (top) and one axial PET scan (left) show marked glucose uptake in the central region of the collapsed lung as well as cirumferential uptake in the periphery of the lung. The glucose avid lymph node (arrow) in the left axilla was biopsied and proved to be inflammatory.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9665=[""].join("\n");
var outline_f9_28_9665=null;
var title_f9_28_9666="Horizontal shoulder abduction prone";
var content_f9_28_9666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Horizontal shoulder abduction while prone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 202px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADKAgQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6O8T6+NBXTlXTr7UrnULr7JBb2ZiDs4iklJJldFACxP8AxelUP+Ep1f8A6ETxJ/3/ANO/+SqPGf8AyMXgT/sNSf8ApuvKyD/aWo6x4wubjxdqukadpF4sKRWsNoY44hZW8zMTJA7E7pHPXpjik272QGt/wlOr/wDQieJP+/8Ap3/yVS/8JTq//QieJP8Av/p3/wAlVxXwu8QR/EnTLy80Hxv4whFpMIZYbu10xJBlQVbC27Daecc9jxXffD3ULrVvAPhrUtQl869vNMtrieTaF3yPErMcAADJJOAMUm2gKv8AwlOrf9CJ4k/7/wCnf/JVH/CU6v8A9CJ4k/7/AOnf/JVdTS4qedjOV/4SnVv+hE8Sf9/9O/8Akqj/AISnVv8AoRPEn/f/AE7/AOSq6k0Yo5mBy3/CVat/0IniT/v/AKd/8lVR1Tx9daWkbX3grxLEshKqfMsGyfwujXb1R1qzOoaZc2y+XvkQqpdcgH1pObtoOKV9Thx8Vosf8il4kx/vWX/yTWrY+NdQvoBNbeBvE7RHozPYLn6Zuhmn6B4MgsZFn1CQXMq8qgH7tT64PWuuwAMClGcnuXUUF8Jy3/CU6t/0IniT/v8A6d/8lUv/AAlOr/8AQieJP+/+nf8AyVXUUVXOZnL/APCU6v8A9CJ4k/7/AOnf/JVZl38RZrO4eC48GeJUlXqu+xP8rmum1TX9N0zK3Nypk/55p8zfkK861nUhqeqzXSoUR8KqnrgDv71E6vKtDejR5372xt/8LLb/AKE/xJ/33Y//ACTSf8LMb/oTvEv/AH3Y/wDyTWAjcc9aVn455FZe3kdP1Sn3Z0lp8RJruURW/g3xGzkEgGWwXp9bqq5+J4BOfCHiT/vux/8AkmufLYIGeR0qGRwOc5I9ulH1iXYX1SHc6U/FFR18IeJP++rH/wCSa0bDxtfahbLcWfgnxJJCxIDedp45HsbquBlkyK9F+G+7/hHmY/dadyv6f1q41pN2Mq1CMI3Q7/hKdW/6ETxJ/wB/9O/+SqP+Ep1b/oRfEv8A3/0//wCSq6iiq9ozlscv/wAJVq3/AEIviX/v/p//AMlUf8JVq3/Qi+Jf+/8Ap/8A8lV09FL2sgscx/wlOrf9CL4l/wC/+n//ACVR/wAJTq3/AEIviX/v/p//AMlV09FHtZBY5j/hKdW/6EXxL/3/ANP/APkqj/hKdW/6EXxL/wB/9P8A/kqunoo9swscx/wlWrf9CJ4k/wC/+nf/ACVVTVvHV5pOl3mpah4J8SQ2VnC9xPJ5tg2yNFLMcC6JOADwBmuyzXK/Fc/8Wt8Y/wDYGvP/AEQ9Cqu47Gp4n18aCunKunX2pXOoXX2SC3szEHZxFJKSTK6KAFif+L0rP/4SnV/+hE8Sf9/9O/8Akqjxn/yMXgT/ALDUn/puvK5Hxbrt5pcPjnXdR8S6/ZaVod9DbJaaXb2TnY1tavkedCxJ3zseW6dOlbknXf8ACU6v/wBCJ4k/7/6d/wDJVH/CU6v/ANCJ4k/7/wCnf/JVch4R1O68Sa5f6OPFXjfTtSsoIrmSG8ttKOY5BlGDRQOvI7Eg+1dx8PtRudW8AeGtS1GXzby80y2uJ5doXfI8SsxwAAMkk4AAo1Arf8JTq/8A0IniT/v/AKd/8lUn/CU6v/0IniT/AL/6d/8AJVb8up2ETYlvrVD6NKo/rRFqdhKcRX1q59FlU/1p2l2FdGD/AMJTq/8A0IniT/v/AKd/8lUf8JTq/wD0IniT/v8A6d/8lV1IIYZU5HqKKm7Gct/wlOr/APQieJP+/wDp3/yVR/wlOr/9CJ4k/wC/+nf/ACVXU0Hgc0XYHK/8JTq//QieJP8Av/p3/wAlUf8ACU6v/wBCJ4k/7/6d/wDJVXdR8UaXYsyNP50g4KQjd+vSsK58e84tNOdv9qR8foKTnYtQk9jQ/wCEp1f/AKETxJ/3/wBO/wDkqqmoeO7vT03XngzxDED0BuNPJP0Aus1gah4x1a6VlRktUPGIl+b8zWF5jySNJK7M56sxyT9ah1exrHD3+JnWj4oqenhDxJ/31Y//ACTTh8Tieng/xJ6/fsf/AJJrmY1YjOD9cVP8+fukjrwKn2sjT6vDudB/wsw/9Cf4k/77sf8A5Jo/4WYf+hP8Sf8Afdj/APJNYKq2eQRQScgjPHFHtZdh/V4dze/4WYf+hP8AEn/fdj/8k0n/AAs/gn/hEPEmB/t2P/yTXPsCO1QSHB5B57UvayD6tE6Q/FJB18I+JP8Avqx/+Sab/wALVjA/5FHxL/31Zf8AyTXOLa3dxA01vbSywqdrMi7sHHcCnWOiapqMyxwWkwBOC8ilFUepJpqrJ9BOhBbs6/S/H9zqokNh4K8SyiPAc+ZYLjP1uRV//hKdW/6ETxJ/3/07/wCSq1vD2kxaNpsdrEdzfekfH32PU1pVfO+pyySvpscv/wAJTq3/AEIviT/v/p3/AMlUf8JTq3/QieJP+/8Ap3/yVXUUUvaMRy//AAlWrf8AQi+JP+/+nf8AyVR/wlOrf9CJ4k/7/wCnf/JVdRQKPaMLHL/8JTq3/QieJP8Av/p3/wAlUf8ACVat/wBCJ4k/7/6d/wDJVdRSUvasLHMf8JVq3/QieJP+/wDp3/yVUU/jS6s2tm1Lwj4gsrae6gtPtEslkyRvNKsSFglwzY3OucKa6yuW+JP/ACL1n/2GdJ/9ONvQqrbSCx1tFFFbiOU8Z/8AIxeBP+w1J/6bryuP8T6DrPijRPibofh25tLW7v8AWIYJJrlmVVhNhZeZjapJJXIx7nmuw8Z/8jF4E/7DUn/puvKs6p4L8Latfy32q+GtEvr2XHmXFzYRSyPgADLMpJwAB9BUOVmBxngT4Zah4H+IUupaVqi3fh+70yKzuorrYk4lhAWJlWKNUKhAF555JOa6n4Tn/i1ng7/sDWf/AKISj/hXPgj/AKE7w3/4K4P/AImultLaCztYbWzhigtoUWOKKJAiRoowFUDgAAAACpcrjJaCQBknA9684+KnxCbwyU03SVjfVZF3s7jKwKehx3Y9hXhep67q2sTNJqWo3dwSc4eUhR9FHA/Ku3D4GdZc2yOSti403y7s+tDe2qnDXMAPoZBUsciSDMbqw9VOa+NGXnJ64qWK4uLc5t55omHeNyv8q63lX94wWYf3T7Iorz34HX13f+DJJL+6nupVu5EV5nLsFAXAye3NeOePtU1KHxtrkcOpXsca3bhVS4dQOegAPFcVPCOpVdO+x0zxChBTtufUrEKpJ4A5ye1YV/4q0iyYq115rjqsKl/1HFfK0uq6pJGyTanfOh6q1w5B/DNXtM8P+KNU0p9S0yz1C4sUOPMRzzjrtXOWx7ZrWeXOKvzIiGMTduVs+gbv4gW6gi1sLh27GQhR/WuZ1PxVqupEq032eE9Y4Pl/M9TXiiXGpW5dxNex+W21yxbCn0Oeh9jXVeGvET3NwtpqJHmtxHKBjJ9DXNWwNSMeaLujsw+MouXK42Z1cSFj0OT3qzGhHVT+Vef+KtQuotaeOC6miRUUBUcgHisxdW1JSCL+6x3/AHhp08slUgpqW5VTNI05uLjsesrkdQ1Kc9NpzXlsWtaoOTqFz+L0j+IdTXj7fcZ9Q1P+yql90T/a9P8AlZ6a5K9c1BJvZGdEZkXhmCkgfWvMJvEerjP/ABMp+nTj/Cvc/hvcjT/DOp6zfyAwRQhnyeu1dx/nWFbAypNXe5vSzCNVNpbHO6Zpl9q1wsFlCzZPMhBCoPUmvYdJsY9M063s4eUiXGfU9z+Jr5lf4seMWd2j1NI1YllT7NHhRngdO1OX4t+Ncgf2lAw/69E/wrdZbNdUcdTMY1Hax9R5orzL4K+NNQ8VW+pwa3NHLe2zq6MkYTMbDHQehH616bXHVpunLlZcJqceZBRRRWZYUUUmeKTYAaKKKhsYVyvxX/5Jb4x/7A15/wCiHrqa5b4r/wDJLfGP/YGvP/RD0k9QJfGf/IxeBP8AsNSf+m68rj/FXhm88ZeHPipoGmS28V5e6tbrG9wzLGCtlYMclQT0U9jXX+M/+Ri8Cf8AYak/9N15VrVPBXhbVr+W+1Xw1ol9ey48y4ubCKWR8AAZZlJOAAPoK9BuzIOO+G/w/wBS8O+M7rWprfR9GsJNNjsf7L0eRnimlVgTcSExxgPgY4Xoevr4JpGt6nd+FdFtri/upIIbKCOOIyEIirGoAAHHQVFqejaPPql5JHo+nRo07lUS1RVUbjgAAYAxVqCFIlSONVSNAFVUAAAHAAHYV7WEwvs3zS1PKxOJ9ouWOgxoweSMnvmkVAASAAc9q9E8CfDxvFWnyXz36QQLIYxGi7nyO59BXTyfBeHb+61aTP8AtRitamOowfK/yM4YSpJcyPH7TVNQsDus7+7t3HeOZh/I19bRsW01GLEsYQSe+dteGar8HdYh5sLm2uR0wTtNe6ohSwWNvvLFtOPXFedja1KryumduFpTp3Uz5Dk1K/8AMcC+uwNzD/Xv6n3pDqN+6ENfXZUjBBnf8utQMMSv14ds/maUjjIr1VGPKtDzm25bhZxahfXS21hHdXNwwJEUO5mI9cCkmN1aztDctcRTKfmjkLKw+oNel+GbHXLqJLf4c2c2nWE+PtGtXyr5sxHUDjhAegUHPc17LqGg6XqcNpHrtraXt5GqtvZAGdl6kd8Z7dK4KmLjGVuVW/E7IYdyV+Z/ofLen63f2bh7e6dl/uyHep/A13ugavFq1szABLlOJI89Pce1cp8Q9TsNS8WXlxpVi9lbALGYmiEbF14LFO1VfC9y9vrcBU8SAxtz1BqcRQjWpc6VmaYbETo1ORu6Jtcv7n+2bwx3M6L5hwFkIA/AVT/tC9Cri8uQP+urVJLZahqd5dT2Nld3EXmsN6wnBOemehqJtH1ZAXl067VQMkmM4ArohUo8ivY56kavO9yZNUvvvfbbn/v6akbWL9TkXtwT/wBdDWTHJlR3ps04GATituSHZGXPPuzVbXNQ6pfXIz/t9Kjttb1N7yCN7+cq0ighmzkZrPuba7gtWuZLW4W2VdxlaM7QPUmqmkXcMup2qpKrOZV6d+axn7HldrGsHV5lufT3gRxpfhjUNUu2C2+Wl6/wovJ/Q14dc/E/xbJcSyRaxLGjuWWMRphVJ4A47CtvxX4qurHwjc6DEQYr5x82eUXOWA9jx+teY55HHBOK48DRUoczR146pJT5UzsB8TvGQHGtSH6wxn+lWrD4q+K4b22ku9UM1ssqmVGgQbkyNw4HpmuVudKurfSLTU5V22V5I8UL92ZMZ/z7GqDYKgHJXpXYqVKa0SOJ1KkXq2fa8UiTRJJEwZHUMpHcHkU+uM+EOr/2x4A0yR2LTWym1kJ9U4H6ba7OvnqkeSTievF8yTCikoqLlBRRRSYBXLfEn/kXrP8A7DOk/wDpxt66k1yvxI/5F+z/AOwzpP8A6cLeiL95AddRRRXYScp40/5GHwJ/2GZP/TdeV1Fcv40/5GHwJ/2GpP8A03XldRWNTcaFopKKhMD5b+KLyP8AETXPPJyJlUZP8IQYrnV+6Twc9PrXsfxr8D3d/cjX9HhaeUIEuoEHzEDo4Hfjgj6V4qJDHlZAUdeCrDBH4V9Lgq8J00k9TxcTSlGbb2PYvBenfDi/0u2W7nj/ALQ2DzkvJjGwfvjoMZ6Yrq5/hb4Tv4d9pG6KRw8E2R/WvnBjnJPP9Ku6Xq2o6PcLNpV7cWjjn905AP1HQj8Kyq4KTfNGbNaeKilaUUfUfgjwzD4T0iSwtp5J42mabc4AIzjjj6V84fEL/keteA/5/HzXuXwn8cP4ssZ7fUFRNUtMFygwsqHo4HbngivC/iK+3x7r+egu36/hXNhIyhWkp72NsS4ypLl2MvTsHUrUC2juy0qqLeXOyUk4CHvg5Fe86VoDeEpm8VeMddkP2aPyktrVGS1tkbgIqDqBwBwOea848E+HYtMNr4n8WzDT9Kt2EsMMoPnXTDldqdducH3+nNbl/wDGS0uINTthpN3e292WVUvJI1REIxgBVzjvySferxDlVlaGqFQUaavPRmn458UxeM/C1xZ+DVtrl5yWvLeQeXdFVIwyIfvdOoyQMV4tEZIbhd6tHLG4yrDBVgehHrVWL5VBU4KnIIOMe4q9bLLe6hErs8ksr7mZmLMe5JPc1rGCowfYzc3Vku52lr4K1fxdqN9cWMtpEqFRtlkO9hjrjHSotf8Ahnr+g6Rc6neSWj29uAz7HJOMgdPxrp/Cer/2N4gtrhyRAx8mX/dPf8Dg133xjfZ8M9cZT1iUf+PrXmUcXUuop6HoYjCwV5NHzL52FzWv4S8M6n4tnuotISFntlVpDI+3G4nH8jXLLOTHyc817N+zJ8134jfr8sA/9Dr1MTVdOm5Lc82jBTmos841/wALeIdE1I2uoaY6sf8AVyK6mNx6qe/863/E2tXVh4dOk28xSO+VVnj/ALyrg/hzxX0ze2dvfQNBeQxzwt1R1yK+T/ii9lH461G20wMLO0YQKGbdhgPnwfTJx+FebQqTxNWPP0O+ooUKUuTdnOKjNIqhS7MQqqO5PQVt+M/Ds3hfxAdMuG3uIo5Q+MZ3DJH4HI/Cs7w7cLba5Y3TyRosMyyhpBlcqcjIrufi74i0rxR/ZGqafOgvkV7e5hGeB95WB7j7wr0pVJKqorY4YwTpuT3KvwS1b+y/iHaRs2Ib5WtX9CSNy/qMfjX1Ea+IbW8l0+9gvoSRNBIsqkccqc/0r7U028j1HTbW9gIMVxEsy/RgD/WvOzKFpKfc6cFK8XEtUZpKK8q53C0lFFJsBDR1pKKybGLXK/FY/wDFrvGP/YGvP/RD11Ncr8Vv+SXeMf8AsDXn/oh6mMveQE3jP/kYvAn/AGGpP/TdeV1JrlvGf/IxeBP+w1J/6bryup7V6ctyD5R8c6VLoHizUbGVSE80yxHHDRsSQf1x+FY6zLjHavp/xx4N0/xbZLHeAx3UWfJuEHzJ7e49q8W1v4U+ItOZ/sqxX8PZozhsfSvYwuOpuKjU0Z5dfCSu3DVHJafq1/pU5m0u9uLSQ8M0Lld31HQ112l/FfxRZlRPcW94i9p4gCfxXBrjr/R9U04k3thcwgdSyHA/GqasD75rucKVdc2jOZSqUnbVH0D4R+LWmavcx2erQ/2bdSEKkhbdC59N38P4/nXpMn+rf/dNfGPTI4PHSvpX4N61NrXgiIXTl57R2tixOSVABUn8CB+FeXi8LGl70Nj0MNXdT3Zbnze5PnyDsJG5/E1JBDLd3MVrbRtJPO4jjReSzHgCn6bZPqeurYxzwQPPO0YluH2xr8x5JrvE1vSfh1LdWOkWj6j4jQmOa/u4/LSE+kadcfln1rtnVcUoxV3Y5IU7vmloj2zSpBo0GkaKbOc7LVVa4ijHkRlQAQzZ4yc9q+fvinavoPjt5NM1SWYyD7RG63BaS3JJym7OR7exrkNW1nUdXv5LrVL2e5uH4LM5HHoAOAKq8YGBx1rClhXB80mbVcQprlijo9R8SXGs6d5OtWtve3oULFqBBS4XB/iI4cY4wR+NUtBUvq1sAPundx6Cs4sq/M3HHWum8IWLfNeOpVWGI9w5I9aMTKFGm0uo8NCdWom+h638MdWFtqMmmO2IbgF4hnhXHX8x/KvRtVwNLvCQOIX/APQTXgUVxNa3UNxbttmiYOp9wc17U2qQ6r4Pur+3I2PaSMRnlW2nKn6GvEhuetWjZ3PkOCcFR2PtUV24CMM9QcVTt5sInH8Ip0sm8ceuK+k2R4FtT7Y0yGNtGs4njRkNuispUEEbRwRXFa78M7GR2uNCEVrLnd5LL8hPseq/yrvLIbbK3HpGo/QVW8Q6pFomhX+pXBHl2sLSnPcgcD8TgV8zfmlY9uMnHVHyf41aePxJd2VwAstmfKYA5AI68/jWGSxB29cVFcXkt5dz3Vwxaad2kdierMcn+dOjkKMHDcqQR35r6OnDkp8qPHqz55uT6nvfjLS7C9+B1n/ZJD/2UkUxBGGUjiQEdj8xNeESN8o44rag8Za1Ck8UV0oinjaGVPLUrIhGCCP61gs3y/TpUYalOmnzFV5wqNch7T+zbrBF1rGjyNw6rdxD6fK3/ste7V8i/C/WBovj/R7pmCxSTfZ5Sem2T5f5kH8K+uq8vMIctS/c7MJLmhbsFFJRmvPudYtFJRUuQBXK/Ej/AJF+y/7DOk/+nC3rqq5X4kf8i/Z/9hrSf/Thb0ou8kDOvooor0CDlPGn/Iw+BP8AsNSf+m68rp65jxp/yMPgX/sNSf8ApvvK6eueq9RoKD0ooNQmM5DUPiN4c0zxDdaNql29ndW+3Lyxny23AEYYZ9e+KS9TwP4jj8y4n0a53DPmCZA355zXgnxuSWP4m6s7RyLGyxEPtOD8g6GuDLRk8hD+FexSwVOpBST1PPnipQk4taHtPxL8M+C9J0mW50bVYo9RBHl2sUwl8znkYH3RjJzXlbSZX3rOWRF4Xav071p6Ppmpa3dLb6TZT3U7YGI04HuT0Ar0KSVCFpyv6nJUbqyvGJ6P+z8zf8JndyA7YY7FzKx6Ablxn8jXKeJNd/4uDqGs6ZtIW9aWEyoGBwccqe1dzp2lHwhpU2jpKkupXW2TUZkOQuPuwKfQcknuTXkmouo1G7UkZEjdT71xUa0ateVtrHZVoypUI33uXPEGrz61q91qF2ztLMxYK0jOEB/hUnoBUKaRrS2kd4NLm+yyMVSYsApPpmszf5kiRqwLMwQY56n0719o6Po9tp2g2uliNZbeGIIVkUHf6kj3OaMZXdFKNNk4alGpd1EfI1vpOqzMALVIs/xPJ0/Kut8P6MunZlmkEtwy43YwFHoK9f8AFPgbTHRp9OuItOuDz5cj4if8D938PyrzS5hms7p4LgBZV4O1gwPuCOCK8uriatRWk9D1aFClB80VqMmw3Xke9bviXxG2o/CDXNPumzdWaRAMTzJH5igH6jofwrnXfk9M1zvjKZv7IdY2YeYyqQP4hnpj8qij8aNcQr02cJvIANe7/suDdF4lkx/y0gX/AMdavB3t7jp9luCf+ubf4V7/APsuwyx6T4hkmikj33MQG5SM4Q+v1r1cfUXsWrni4aLVRM9Y8W61H4e8M6lq0xGLWBnAPdsYUficCvi155JpHmuGLSyMXcnuxOTX0D+0lrUsWkabodsrs11IbibapOET7o/Fj+lfPqQTHdmCY/SM1jlqjCHM92XirykkkTRebICY4ncA9VUnFOZZU+aSKRF/vMhAr6q+EXh2PRfAGmQ3Nsoup1NzNvT5tznODn0GBWr450K31jwhq1itvHvkt3MeEGQ4GVx75AonmnLPlS0BYNON76nx5IcnnHSvqL4C6t/aXw8tIHbdLYSNatzztByv/jpA/Cvl1ba8ZebS59/3TV7N+zdd3NprmraZLBOkNxAs4LRkAOhx17ZDfpWuOcZ0nZ6ojDKUJ6o+gaKbS189zHpBmkooqXIYUGkorNsYma5b4rf8ku8Yf9ga8/8ARD11Jrlfit/yS7xh/wBga8/9EPUQfvICx4z/AORi8Cf9hqT/ANN15XU1y3jP/kYvAn/Yak/9N15XUV7E9zM8Qk+NV3peu6jY6npUV1Db3MkSSW7+W+1WIGQcgnA9RXQWfxt8MTRgzw6lbueoaAMPzBrwfxzbXEHi7WjPbyxqb2YqWQgEFzg5rCEo9R75r2YYWjUimjzJYirCTR9K6j8ZPCht28u3vbxyOIzbgA/UseK8E1K9W91O7u4rdLaKeVpFgj+7GCfuisjzFGPenxMXbbGrMxHRBkn8q6KNCnQu4mNWtOroyyZOflPPpXuHwxvz4W+FdzqUq/6RezyyWsZ/jwAoP04Jrg/B3w31DVh/aGuLJpeiRDzJZZOJJFH8KDtn1rpddvvt8UxSMQWsUPk20A6RRgYVR/U1w4/FRklCGp24HDSu5y0PI2cuXZzkuSW47k5pZ53lcvLI8jnqzkknHuahEqKpy6D8RxUEtxHz+8T/AL6r0YyiktTgcXfY7XwZ8PNR8Xw3VxY3ohWNd2GAwT2XPqcE0zUPAd/ps/k6jc3kD543IAD9D0Ne8fBPT47H4caVIsbJLdKZ5Sw5JJOPwwBiuzvoLa4tXjvkikgI+YSgFf1rwa1afO7SZ7FKMFFXifLun+GbKB1knMlw6/8APU5A/CuiBUDavQDt0rq/FXhzSIWlm0LVbPf1a0kuFP8A3wc/oa4wSckHgVzSk29Wd0FG3uoe56fT0rX8N66dJttVtLiULZ3lrKOTwsmw4P49PyrCaTBPzVk+IJANJus9BGc4+lOPxIKivFo82j/1SA5+6Kch3TRqM5LqOfqKuLo+qPEjw6beMjgMrCI4I9alstB1qbULRBpd8S00Y/1R/vCvelVhy7o+fVOV9j7YhGIYx6KB+leR/tI68LPwzZ6NE+Jb+XfIAefLTnn2LY/KvX8Y4/Cvlv4ySapr/j++khsbt7W0AtISIyQQvLEfVia8LBpOtdvRHo1r8mh5yG4rp/Cfg3W/FENxNpFuJIYWCOzHAyRnArIj0TVs/wDIMvMn/pka+pPg3oUugeAbCC7haG8uC1zPGwwVZjwD9ABXq4nF+zh7j1OOjQ5pe8tDxEfCPxccZtYh/wBtBXFalZT6VqFzZX8RjubdykiHqDX21Xzf8d/C+oyeOTe6bYT3EN5AjM0SbgHX5Tn3wBXPhcfKU+Wo9DSthoqN4LU8oLMCCrYcHKkdiOhr7Q8Iasuu+FtK1NTzc26O3s2MMPzBr5Gj8La/vz/Y16R15iNfQ/wITU7bwdLZatZ3Ft9nuW8kzLjcjYPH0Ofzp5hOE4Jp3aDCxlFtNHpNFFJXi8x3C0hopO1JyGLXLfEj/kX7P/sNaT/6cLeuorlviR/yL9l/2GtJ/wDThb0Qfvr1F0Owooor0yDk/Gn/ACMPgX/sNSf+m+8rp65jxr/yMPgX/sMyf+m+8rp65a3xFIWg0lFZ3GV7qytbtdt1bRTD0kQN/Ose48FeG7g7pdFsmPr5YFdBmuL8W+PLPSN9rp5S81DoQD+7j/3j3PsKafYFFy0LF14U8HaTD9pudL06BF/idep9h3rnNW8ZJHA1p4ZtI7OE8GbywrEf7K9vqa4271S61W5NxqEzTS54LdB7KO1DSp2puTZ1QoRWrEO4lmYlixySTkk+9ZVzommzO0k1nCZGOSSvJPvXSaJpV7rd2YdPiyi/6yVuET6n19q6bTPh3dTsG1a5SGLPMcHzMfbd0H60lJouTgtzy238MwTybtP0kzPGc5hiLbT+HQ1uS3PiK2j8uaXWI0A6N5gFe9adZW+m2cdrZRLFBGMKq/zPqask8USl3MFVS2R8xzSNK5M5kd/70hJP600S7flUdOwr6aaKNvvRofqopBDED/qo/wDvkVPtEP23kfNCrPNxFBM7HoFjZj+grq/A3g/U77XrK71Gwkt7G2kE5adcbyvIAU8nmvb1AUfKAPoKCaTqidVtWsRG2gJyYIif9wU5ESNcRqqj0UYFPoNYSZkRSW8MpDSxRuRwCyg4pos7Yci3hz/uCpxRST0AXtSUUVVwI/Jiz/qo8/7op6qq/dUD6ClpKTlYBaM0maKjmGFGaKKVwA0lBoqWAhP5VyvxW/5Jd4w/7A15/wCiHrqa5b4rf8kv8Yf9ga8/9EPUx+JDLPjT/kYfAn/YZk/9N15XUGuX8af8jD4F/wCwzJ/6bryunr2Kr1MkVrvT7O7BF1bQzZ/voDWPceCvDlwxMukWhJ77K6HNQX97b6fayXN7MkECDLO5wBUJ22Ha5zqfD7wurAjR7Yn3FMvZfC/hX5Y7S1W6A+WGGMF//rfjXKeIvH1zfyNb6QWtbXoZTxI/0/u/zrl12uWdiSzHJJOc1TmzWnRvubXiXxHe682yYCCzU5SBTnPoWPc1gldyFW4B61KzKBx2pq5csUQsFXcxAztHqfSov1OlRSVkY82g6YWLGzgyevy1Tl0TTB/y6QD/AICMGu00rw5q2rvi2tHSInmaYFEH58n8K9Q8N+FdP0S1VREk90fvzyKCSfb0HtT5mZSlCJ4ZZ39zYwrDZ3k8ES8KkczKB+GabcXk90xNzcTTD/bkLfzr6NlsrWUYltYHHo0YNULjw1olx/rdKs2/7ZAfypXRHtV2PnncijoMfShpRtzu5r33/hDvD2f+QRa/98mlTwh4eU5XSLT8UzRzor2qPn9pgepAPvVnSdFvvEF0lrZW7yJKQrybTsjXuSelfQVvoGkW+DDpdkhHfyV/wrRVVRQqKFUdABgVLqWJdQitraO3toYEVdkSKg47AYqXYo6Ko/ClorKTMgFN8tCc7Vz9KWl7VCYxuxM/dXP0p1FFVcQtJRRRcBaQ0UlJsBaSiipuMU0lFFJsArlviR/yL9l/2GdJ/wDThb11Nct8R/8AkX7L/sNaT/6cLenTfvoHsdhRRRXrGZyfjX/kYPAv/YZk/wDTdeV09cx41/5GHwL/ANhmT/033lT+NfESeGtI+1eWJp5GEcUZOAW65PsBXJX+NFR1Ogrm/EHjTRtF3JNci4uR0gg+ZvxPQfjXkGteL9b1gMtzetFA3/LGAeWv445P4msvTtKv9TfbptjPckdTGnAPuegqUrG6pfzHQ+JfHmq60HhiYWNmePKib5mH+039BgVyYcAdsV2+k/DHWbsh9QmgsYz1GfMf8hx+tdto/wAONCsNr3Ucl/KO85+XP+6OPzzQ5JFc8Y6I8g0q0vtTl2abaz3L+ka5A+p6D8a9B8PfDe6lZZdeuFij6/Z4Dlj7Fu34V6dbwxW8Qit4kijHRY1CgfgKkqHU7EOq3sQWVnb2FslvZwpDAnCogwKnoxSd6htmQtHeqP8Aa2n/AG/7EL63a87wLIC4+oHIq4WGQM9elJvoO1txaM0uD6UmD6Gpal2AKKOaSoem4C0lKBnpUF8Ln7JL9h8n7Vt/d+cSEz745xT5WwJqWvItY+Kur+DtUgtfHnhoWtvOSIrzT7jzo3A6kBgMkdccH2r03QtY0/XtMh1DSLuK7s5RlZIz+hHUH2NNwktxmhR3oopMBDSUtJWbAKM0GkFSMWkrJ8Ua7Y+G9FuNS1O4ighiHy+Y23e3ZR6k+grntF+IVheMBd+XErMF8yJtyqfRvSiz3NqWGqVk3TV7HbnpSetJG6yIrxurIwyGU5BFOPNJoxG1y3xW/wCSX+MP+wNef+iHrqTXLfFb/kl/jD/sDXn/AKIelD4kDLXjT/kYfAv/AGGZP/TdeV05Pc9K4P4t6r/Ycvg7UfJ88w6y2I923JNjdr1/GvOvEXjDWNcLJc3Hk2p/5d4PlU/U9T+Ne1UV2TCDkeneJvH+maSXgs2F9eDjbGfkQ/7Tf0FeUa9r2oa9ciXUZywB+WJeI0+g/r1rF+6v+FS2sFzfTiKyhluJT/BEhY/pUWsbxio6k6Sbe/41ObsBc5AHeul0T4b6zelXv2i0+Ejo53yY/wB0cD8TXf6F4B0TS2WSSE3twP47j5gD7L0FJtA6iR574Y8Nalr7rIqG3su88g6+yj+L+Vet6Joljo1n5FnEPm/1kj8tIfc/0rSACgBRgDgAdqWs3IxlNyFozSUUcxIUUUVDYBSUGiobYBQaSilcYtBopDQ2AdqO1ANFJXAXNFIKWmgCkpaSkwCiiipYwpKKSpbAdSUUmaTYC1y/xH/5F+y/7DWk/wDpwt66fNcv8R/+QBZf9hnSf/Thb1dP416oTOxooor2DM5Pxt/yMHgX/sNSf+m+8q34q8O2niTT1trtnjZG3xyp1RsYz7j2qp41/wCRg8C/9hqT/wBN95XS5xXFiHaaLifPPizw1feGbpY7rbLbyZ8q4UYV/Yjsfau5+DfiBZbaXQ5gFkhBmgP95SfmB9wT+RrvNf0i11zSprC+UmKQZDDqjDow9xXm3g3wNrGi+OIri4KmxtldhcIwxKCMBcdQeefpUc6ktTXm5o2Z61RRRWDZmFeY/HD4nR/D7SbaCzRZtbvwwt0cZWJR1kYd8ZAA7n6V3HiXXLTw7pMuoX7ERJ8qqOrseiivgT4s3uoXPje/utRZmkuHMyOWLBlPTaT2HTHataCU5WZXK+Xn6G3qXjnxbrGpeedd1K7lYEt++MaIOuAq4AH4V1XhDxT4v1jQ7q0PifU4ZVkCC2ZzJ8h6N5n3lXPB54ryrw/aXOs3CWlluBP3yDwPcmvpDwHbaL4YOmabDbW5v5o3M86kF8jBKt7e1GLmqUbRWp24Kj7WV5bHsPwq8KWfhvwpZhUjl1G4jEl3dhfnlc8nJPOB0/Cuy2Avkk5xXCeBtaiGr3ukwzvKsn+lRBmz5Y4V1X2zg49zXfKBu3Y5rfDVFUgnH5nJiqTp1HGQoGPX86Qbtxz07GmySBASTgCoYrpZDxwMZ59PWtnVSdjBRLVJtGegqATgrlQTnoPX3qUNhdzkD1NCnGQWsOqjqNylrtaRgFbPWrZcKhZjxXG/FC/Sw8PQ3m47RKI8r/tA4/lWVZKpBxRUPi1MP4rW9l4r8BaxpsgBnWBri2fHMcyAspH5EfQmvjvwr4z1fw9L5+iapc2MkoAkEL4DfUHg19Cv4pBjkxCxjKMSS/OAp4r5HEg8xiuQu4kD2zU4em4xaZdSS+ye32Xxm8fQ4dNfWVQcET2yMPzxXU6X+0T4ntkxqOnaTff7SloW/TI/SvnOK8ZeAxx6dqkOoSdd1bOkn0I5j6Zl/aV1MD5PC1v90/8AL2zc/gvSsLUf2jfF0+0Wel6daADk+U8hJ/E14EmpyjGD79Kk/tZ9wyoI6HqKn2Eewcx7RF+0T42juVlkWwliU4aE2mAfxBzW1Z/tK+JUZhd+HNOnBPHlvJHj065yK+d5dQ82UMyYHfDdcU+O9MfHmFh23ZyPxpuhB9A5jsfil4z13xx4gXU9Q3RiNBHFZxZMUKjrgHqT1J6/gKxvDmsSWlwskN1dQSs4yV+ZSfR0PUe9Z0WrMjAhyf51ONT84fvnVcf7IquRWtbQqE5QlzRdme6aH8ff7Cn+w3Vk6eWRuaGTzYj7hTgj6ZrsdY+NT6vaSf8ACP2eoRrYwi4vbuGLckPOBuB52+uR/jXyddX0YO62jXJOH+TGa3rrxHqsngqW3tpzbadO6QXgSTDXBXlA4PLAVhLCwb0OxYtyfPUSbXlv/XmfZnwl+JNn48s7iHAj1ayVTcIo/durZw6H0OOnY1sfFY/8Wv8AGH/YHvP/AEQ9eK/sl6laaL4e1KLVLmzt1vJke3YkbnwCDubsOmAff1r2n4psr/Czxe8bKyHRrwhlOQf3D1wzhy1bI5pNN3SsYX7QAZtK8KqgLO2thVA6km0ugBWJpfwy1m7CvfTW9khHKn94/wCQ4H51s/tCMyaP4WZGKsutAhh1B+yXXNdV8P8AxD/wkXh+OeUj7XCfJuAP7w/i/EYNelWbTIi2o6GbpPw00O0w14Jr+QdpW2p/3yP612FlZ21jEIrK3it4x/DEgUfpViiudyYm29wooqC7uYLO2lubuaOC3iXdJJIwVVHqSaSdxEskixxtJIyoijLMxwAPUmuck8deFY5mifxDpm9Tg4uFIH49K+SPin8VLzx1rVxF5s0Hh+GQpb2quVDgHG+THUnrg8AGvPYlvZBNPalI4k6bzw30rX2TKSXU/QyfXNKt9PN/NqdklkP+W5mXZ+ea5TTPiXp+ua62meG7C+1Mx/625jQJCg9SzHp+FfKfg/RYNW0EySSSxakkuyTyQGjjDH5HYZxt7E9a+tfg3ottoPgSys4cm5BY3TMBlpc89Oo9PbFZRSlP2admbSo+zpqo1dM7FGJTLgL+NOX5hnI/OkuHVFXcpfcwAUDOTUoAA4ArpVGNtTlbdxuw+oo2GnHBIyOnNKOKfsIMLsj2Gm4OehqeipeGi9mPmIgpoK7etS0jDIxR9XilpuK5xfjrwFo3jGMHUDd214i4ju7Sdo3X2wDhh7EV8+69qvjP4OeKo7H+2Lm8sJB5tv8AaGMkFzHnkEE5Rh0ODx1FfS15q8Vu7I7/ADA4IAryP9o1LbXPhnd3KoftWlTJdRPwTsJ2uPxB/SuWnUblZrQ3dNpXOp8MfGzwfq9lE99qC6XdlR5kNypChu4V8YI9+K6e38f+EbhgsXiTSST2Nyo/ma/P+C92n5W4PUHvVuOBZ1Yq8gIG44GQB6/Sul0UZH6J2OoWV+m6xvLa5X1hlV/5GrBFfnRAJrOUSWd+8Ei8hoiUI/EGumsviD45sVVLTxXqBUDAD3BYf+PA1EsOmB94kUYNfCk3xN+IcqIjeI9Q2oeCkiqTx3IHP41h3vijxXdSb7nWtWmcnq14+T+Rqfq3mO5+g+DSY5r87IfFPiKG4FxDqmqpOpAEiXbhgf8Avquitfid8RLaUyw+JtSZjzid1kGfTBGKTwvmFz7c8UeINM8L6NPq2u3iWdhDjdI+TknooA5JPoK+btb+OOn6nr91dmK7g04FI7ddx3lB1cqDjrzjOcV5T4w8YeK/GVjFF4k1Ca8hjbesPyqiNjG7C8E/WuKENxZFDJG4jByCoztPrVxwsbe8a0a86E+eG59peBPinbaiyxyXC39ocATR/eT/AHvX+ddh48uoLvw1Yy20qSIdZ0k5U/8AUQt6+JvDOuNZahJd2rppl2keTcRkCNx6NGeDXZeDvijrPiDxV4c0i/S3aKfWbBWkiUpkLdxMDj6qKlYeUZprVHTXq4bER57ck+y2f+R9vUUUV3nmnJ+Nv+Rg8C/9hqT/ANN95XS1zXjb/kYPAv8A2GpP/TfeV0lcGKfvr0LjsFFGaCa5LlBmkoJpMj1pXAwfG/hi28W6DJpt3LLD8wljkjPKOAcEjuOelfFvxN8Ma/Z6n/YWpWQn1CCULbtAd3mKxwNo6kNxx619459a83+NvhRde0GLUbeeK1vtOJdZiMEof4d3bnBrSnPklzFxlK3J0Z8deHGk8OTvFdq0M5Y789PlOCM+x4rodGvNP1DUpb2a/ms7hiVFzJkxrnrjHSud1OYWNze2F9bEsAUMTNteKQdHB7HP5iqcl5NNZJG0drFIBh5kBDMc9cdAccHjmu2VPn1NKdZU7Lse7fAbxBZz/E2ztvtUjl4Zwgdu4XP45wTX1GsrkZZcL2r839A1M+GvEOnazp0u67sZ1mXJzuweQfqMivufwN44tfGulf2hp8U0UBIC+b/Hkc4x6HiolTdPSOxnOp7aXMzrtU3GBTvxHn5/celVWubbIFxd28CnnbJIFJPuP6VznxW8c6X4F8Iy3epkTXsi4tLNWw80nbPouerenvxXyP4u+NXivxBFJblbLTbNhgx2UAGfqzZNONJvUhysrH2pqHibw9o6ibV9d062BPBkuUAb6DNTWmvWWrGEafMs8MmWV4+VcAZ69K/NwTQY5XJ/2uT+tTW2o3FqSbS6mhypQ+VKyZU8EcHofStfZ6WuRfqfokvi3w7c3r2ceu6WWgcRyj7UmRI3Cp15PtXm/wC0v4mt/Dnh/SbKTIS8uDIxGCcIOBjr1PXGK+LDIhHEan6DkVZn1C7uTF9pnubny08uPznZ9i/3Vz0HtTVJJ3C7PTL3xvp50O/EE5a5eBo4kCkHLcf1ryIZGARyPUVeEtwekUhHrtNI/wBpZsiKXj1WrVkJ6lMEg55/KlG48qrE/Sru27K4aB/qKFjvgcKjc9jgU7oLFQQzMu4RtjOOlOFvOf4PzNWzb3rHOzH/AAKkWzvGbhefXNLmQcrKptZvRfzoFrLjqo/Grw028YngH6ZqVNFv36Iw/wCAGjnXcahLsZXlyLngEexpDuB5UitpPDuoN/yzl/79mrEXhTUX/wCWcgPsv+JpOpFdSlSm+hz4cbMFu/pVrTjaLcI16rywoRlAcbq2x4OvhjerD1yy1ND4KuG5Z1/7+CpdaFtylQqdjqdM+I2naZbeRpuh21rF/sHOT75rctfi9KdB13SXVvsGpaZd25iJ4ikaB9rL6c4B+tcHD4JAYieeFQeAzykBfcnHSvZ/Avw48NwfAzxP4hmsYbvWY7HURFduzNsCwuBtGcZHPOM1zSlRv3ZclUUfe2PYPjtZXOo6f4WtrGIzXDawSsY6ttsrpjj8Aaq/BPTry2XVLm4imhgcrEqyKVLMuSTg+mcV1njX/kYPAv8A2GZP/TfeV0taYiVnYxi9LC0DikorlbGLXzX+1L4mGp6GLDSj9otrKbN0yscB+g4HUD1OetfSdfJnxV0S98C6wyXm6907UfMMc2zAcEncjDnkA/j1pqTurGtFQbfOfO1vcYlzJk55Oa6vw5o154ivY44QzQZUMcdia5W9tETUZIbZ98Jb5GPUD3r1Pwhq/wDZWnxpAFzGnVe5x1rtqytG8RUYKUve2Pb/AApYaB4dvodJsbSOK5+zgyTDkyDPIb157V0eg6jNo3xGiihmaay1iAxmJn+WOWMErt9MjIx9K+f/AA5Nr0N02qW9wL19nlRxxtkKD7/rV6fxNqouo7wTol5ZyLLFKG43DnBHp2NeVGjOFTnUj2Jzp1KTi1bsfZUL+ZEjkYLDODUhIAJJ4FcxaeJUv/C0esWq4L2vnrGRkhscriuV+M3i9tI8L6YtlKBJqNysTMOyBS5H44A/GvU9qoxfkeJGm5TUdrnoialZyymKKdHcdQpqyjhxlGDCvGND1sywRT71WTqMGuy03Vor3BS4e0uB1b+FvpXDQx3PK1TRnfisulRXNDVHbM4Vcn8PeljYsMsMVjWtzPuBmv43A6jyME/iDVq41BI4maJXZugOO9d6n1PNcWjQ3ZbA7UbhuxkZ9Kz4mFtC0kjgnGTz3psdvLIFm3EOfmxRzj5Tyzx3q0On+Iby2llIZW3hR15wR/M1wPjrXre58D69bSLKqmydSQepJ4P54o+JuvW2oePtUlt5EaON1twwOdxRcEj8c/lXA/ELUlh8F3iqw3XLLEOeTzk/oKUYK9xubseMxSEY5q3DcsowCR7g4qgpx7U7djvitzM1TftjG403+0XDDB/Sswtx15pGOeTSA101Ju2Dj8Kb/ahyQUGDyCDzmskkDAyDnnjtSbugGTiiw7mk96s0+SpUE84NOjuTG/EgdOytnj6GssknoDj6UuWxja2KdgubX28+qnPUA81ZTWZUChTj3rnNxUjII/CnB8E4P60rBc6MXSZ33Dx4PUYBrV+HV3u+J/g+KHHlNrNl0GM/v0riN5PSus+Fv/JTfBwxyNZsuf8AtulFgufo9RRRVCOT8b/8h/wL/wBhqT/033ldHXN+N/8AkP8AgX/sNSf+m+8roia83GStNehpDYdTWbFMLUxm964ectRFaTrzxTd9RsRSck+1Tc0UUS7ziub+JJ8z4f8AiBGG4NaOCPwrfNYHj/nwPro/6dH/AJVVyox1R8r+FX03xV4c1Kx1/T4bnUbC23W98yfP5QwAGYc5UkDJ7fSubl8HadFBG7XVu4kBOA7bkwccj3rvP2cYEl8Va9DMqvG+kTqQRkEZWs74e6XbzfEXRYbhPNiN4gKOdykZPBB4NdjnKEmky+VSWq2PPLvQNPhOBLCfcMa7z4ZfEK68BaJfWGm2UN7O8nmW0s0h8u3yPm+XqeecZFfWg8M6Qh+Swsxz2tkH9K8m/aO0KKHRdEvLWBFjjuXhkKIFxvX5c4HqtTHEylpJEKEG9DwbxJqV54t1F59Ynlu7qc/O7LuPHYKOgHoOKqw+Dww+S2unz/ds2P8ASu7+CMYg+MeipKMB0nUfXyz/AIV9YtBGvTd+Boq1pw0iW1G9mj4jg8ESn/VaXqrH/ZsT/hU8ngW7htpLifRtYjt4lMkkslttVFAySSegr7SMaerf99GoL2ztr6xntLmMS288ZjkjfJDqeCD7Vh9aqX1HaFtEfHHhzwbL4gsTd6Fpd9qNqHMZmgI27h2z6jIrdi+FmuN08OXo/wB6dV/rX0/oPh7SPDun/YtE0+3srTeZPLiXA3HqfrwK0QidkX8qU8RUcvdegRatqj5Xh+EniBjzoKRj/ppeL/jV6L4Pa3/0DNPT/eugcV9N4Qfwr+VAZc4AGal1qncrmXY+bk+DesnH7jR0/wB6Vj/Srlv8GdV4zPo6euI3b+lfQhY8cU5cnnoKl1aj6j50uh4VF8EtQfO7VbGMf7Fox/rV2L4IyDHm66B67LID+Zr24A44NGxyejflRzT7ke1Z47H8FbUYEmtXh/3IEWr0HwU0g487VNWfHo6L/SvVRE+PumkEiRM3myKmP7zAUe/3FKtK2jPJ/FXwq8P6N4U1XUIZdRee2tnljMlxkBgOMgDmvFfg7Zr4n+IlnpWrMZ7BvNZ4h8m4KpI5HPUCvpT4qazpyfD7Xol1GzNw9syrEJ13MTjgDOTXzj8BtS03RPiFFqes3tvYWUcUwM1w4RQSCAMnua6qUHyu5KqScW7n0jH8L/B8WMaJA3+/I7f+zVW8SeCPC2m+GNYu7bQ7BJYLKZ0fy8lSEJBBPvTrj4xfDyD/AFnizTj/ANcyz/yBrkfHnxt8CX/hTWdN0vWzc311ayQQqltLhmZSByVAHXvWaw877MxVRt7nhfgzT4757F7gPLJLd28Z3Oe7gdK+sPidbQWnwq8Xw20McMS6PeEJGoVR+5fsK+WfCt7b6LYadql6HNrZXkM84jGW2ockAdzxXfePP2jvC2t+Etd0jT9L1gzX9jcWsckqRqql42UE/MTjmtlTlUlePRmuI92yPdvGv/IweBf+wzJ/6b7yulrmvG3/ACMHgX/sMyf+m+8rpM1vin7xyxClphbFG71rluirD6w/Gnhu08V+H7nS735RIN0UoGTE4+6w/wA9K2N4pQ4z1pqaCzPhzXtOh0SXVbC6sLeTUhOIjcsDhUQncFX/AG+Mk9hiuTu7ZVsmvbWV4dP83y7lE+ZrYn7px3U84r6P/aMtNOuNb02xm8u0ub6FjBdnhfNB4R/9lumexxXzd4i8NeIdFJbWdGuYog2BKvzox7cjiu2lPnWu5bVle2hchvpNAgEun6nGHZB/x7S5kkVs87en1zyM1zbajqZRggZUbPU5pySFEJis5j6sIzxUclxdsufs0oU9MIa3UUiJVJPQ9u+GXxljh0VdE8Zzy2fkr/o+pQxlw2P4JEA/8eHpz60zxd428P8AiSw/s86/GsSSieGZ4nHluO+Md8kYrwspcuSBBMSecFaI7W9BysEn0K0nCN7k80j0RvGdxZXccNvqNtcrGcCSFiFf8+ldx4F+JAN/Fa6pNiJzgs56V4K1lcuD5lmc+oYUsVjOsql0kEeeRvFc9TCUpqx10sdWpu+592sNJ1bSzam41COcAOJreUxBCegDdDx1HNcXHH4n0uWJLbVtG1NoJN264imjkcA/dLBioPbOMd68Bs/iNfW/2JGaVreB1Lorn5gMAj8v5V7HeePNFtLSG4t7pHWaNZFQH5s9CPbiuKUK9C0YbHbRWGxF5z3OI8bfFf4hnVWvpru202G0nKtp0CBkjYHGJM8v9elO8OftJeLtNt7iLWILPWC4YxTuPJeNj0BC/KVHpgH3rzj4gaymv+Lru8tVwtwqBtowCwGCT79M1hroVySCrnp2Q16cGuVOR5NSFpNQ1QX2ozX+oXF/PcSfaLiRpZGjOxdxOTgDoPamXFw15Gi3FxPOiHIDPnBqwnh25boZSfaM1Mnhe5IOEuc+yVfPHuT7OT6GG8cIz98D604RW7D5Cx9ia3l8KXTHHlXHHqAKmTwbcEfNBLn1LgUvaxXUfsp9jmNsCkhlY496k3W3GyMH1BNdOPB0xXlCPrLUq+DTj5vIz15kJpe2h3H7CfY5QTRj7sSj8KBdAEYAFdb/AMIjH0L2w47sakh8KwK2DPbE9cYzU+3h3K+rz7HHfa8k5xj6Uhum45HFdwvhi26faYfwQGpYvDlmpwsznH9yKl9ZgP6tM4Azu/UFvXim5LMMRfhtr1KDwgk6nyoNQkHbZA3P6VFfaDYaY4j1Bbm2kwDsuMxnnpwRml9ZjeyH9Wl3PMjBIwyIXx9K6j4WwTJ8TvBzPG6qNZsuT/13Su70DwZLr8Mk2h6Jd6jBG2x5YTlQ2M7Sc9cEGuk0f4e6xoniDw7qV34flsraHWdO3TO6/Lm7iUcZzySB+NCxMXJRE6Fk3c+wKKKK6jnOR8cf8h7wN/2GpP8A033lbkhbtXC/HPxRZ+DLLwpr+pxTy2lnrJ3pAAXO+yukGMkDqw715pc/tT+HgT9m8OarJ6eZJGn8ia83GUJ1JpxXQ0hJLc+ghkjkikI59a+ZLz9qrr9i8Ij2M19/glZF1+1Pr7Ai28O6TH/10kkf+RFcywNU09qj6xZO/WlAwehNfGlz+0z44lz5FvosA/2bZm/mxrLuf2h/iLMCF1a2hH/TKziH8wa1WAn3B1kfcAUntWF48ib/AIQrW8ggfZX/AJV8S3Hxs+Is+d3iq7UekaRp/Jah034jeMNW1e1tdS8S6pc20z7JIZLhijg9iOhFW8E0r3CFX3kerfs6xY8aas2T/wAgqcY7dVqh4EyvxK0AhgqC+Qsx9MmuLt7LWLg+boEV40lvcK1w1ruG2PqdxH8PHetTWLS41C1vbeyjMtzPH5cUanBZieAKiSTktTtUXaR9l3Wr6bbs3n6lYxD/AKaXCL/M1xPxM1zwxqvg3UbFtd0eW4ZQ8MSXcbuzqwICqDkmvjqP4WeMXGTozr/vyoP61o2Xww8VaXMmpXVlDHb2p82Q+epIA9gap0KK+2csFUUk+U7zwVq+m6D8W9M1XVrhLLTbZZA00uSqZQgdO+SBXt198cvhxb5J8RiX2itZW/8AZa+ZdV0i48QywafZmP7VdHapkOFz15P4UxPgn4gyBLe6ahPYOx/9lp8lFpe0dmaVo1JTbgj6DuP2iPh9ET5dzqk/+5ZkZ/Misy4/aa8Gw5FvpmuT/wDbONf5tXi8fwQ1M8zavZp64jc1bh+B0hH77Xox7JbE/wA2pWwi6keyrvoelXP7UuiBcW3hrUn9N9wi/wAgaybn9qfr9l8JL7GW+P8ARK5WL4JWI/12uTnHXEKj+tXE+CmiooaTUtQk9QNg/pT5sIv6Y1h6/Ytz/tR60x/0fw1paHtvmkf+orPm/ac8Wtu8jStDiJ7+VI383rUg+D/haPHmG+lz6zgZ/IVbX4VeDYiN1ncNn+9csf5Uvb4VbRKWErvqcfP+0h49cny30mH/AHLMH+ZNZ9z+0D8RJhgazDDzn93aRD/2WvTYfh54PhcY0SJ1/wBuRz/WrsXhLwrCMxaBpoPqY8/zo+tUFtAf1Ko95HiM/wAaviJOTv8AFV6v+4qJ/Jazrj4meOrzIk8U62+f7ly4/lX0ZDpWiW5Pl6Tp8fpi3T/CtGIWcIHlW1sg/wBmID+QpPHQW0ClgH1kfKj6x4uv8+ZqWv3OfWeZ8/rUa6J4nv3/AOQfrE5P96KQ/wA6+tluxjMeOfQUrXO7j5gR6dqn+0X0iWsvXWR8w6L8PfF0d7DdP4e1ERIclmjx2461f8R+HtUt9MNlc2E9vPIyuPNUqCB6HpX0Rfa1NawEB5GUHBB7Vs6FfWesWr299bxXULjDxyrkfrWMsfU5lJx0N1gIqm1F6nxwvhLUCuSqD8atQeF7izZbmaZcRHJUKefxr6h1/wCGFtMrTeG5FhYcm1uGJB9lbt+NeXeMdMvtJsJbfU7VraUlQFZMZGezdPyrqhjvaaI8uVGcJJSRm/YVu/BBg3lRM+0sFyRxXI3ngy2tdNu7hZrp2hhkfJChchSRXpOnRk6JpygjmRjg9OBVDxJHKPD+qkRmNfssuQQefkOcdqmlVcW0urNMXo4ryPq7xv8A8h/wL/2GpP8A033ldCzVzvjn/kPeBv8AsMyf+m+8rdc+9XjH769DCmrgWppamsQBTeT3wK4r3NrEu7BzSbqaQKTPpTHY+dv2sV33Oibunlt/OuZs7681z4VC51NGmgtLsWrzBueFBUt+eM+1dX+1WmZNFx/ces/4WoJfgT4vjfDL9q7/AO4tdC/h3XRmidmvM4F00eWS3g0+G6kkkQK8YkDFpOeFA6jpiiTwzqMxP2fw/qznsfIk/wAK1vhlaxL8RtDwiArfR8qMYr67e2iz1c/8CpTqSi/d1B2jo0fGMPgXX5nUjwxqrD3jI/nWnF8O9fcYTwleAY6uwH9a+uDbw9w34saT7PD/AM8wfrWbrVWCcUfJTfCzxVLzF4a2H/bmQf1qR/g94tuIHjOkWUYYdWukBBr6y8mH/nmv5UeXHjAjX8qXtqq7C919D5A0v4B+MLe486RtMGDlA11nb78Cuuk+Dvie/itlvZ9CikiG3zULFpB2DfLjivotLeJCTgnPY9qfGiRn5Fxn8amVetJ62KjywVonxt4W8OXGsfEW78MQAQXFo8qPdNGTDmM84wM89s16snwd1POZNehB/wBi2Y/1r3SKGNTuVfm9acWIPWnVqSlZx0FCTR4mnwZmb/W+IZ+f+edr/i1WIfgrbg5l1vUX9dsSivZMnsaC2OprO8urL9o+h5NF8F9KA/eX+qvznqi/0qyvwZ8PkYkbVH+tyB/IV6d5mTgdRQzHBxmjXuxczPOIvhB4Xj/5crl/9+7Y1oW/ws8KJ97R4n/35nP9a7ZAfx96mRc9+aSTfVilNnJw/DrwrEfl0LT8+rIW/matxeDPD8P+q0XTFx6Wyn+YrpAhboCaPKc9mo5GyOd9zIi0HTYv9XYWSD/Zt0H9Kv29jbxnEcca/wC6gFWfLKLliAPfiqk2oWNs4+0XtpH6750XH5mj2YnO/U0I0CjAJr5M/adYP8QZl6lI4R/45n+tfS1z408K2QJuvEmjRY6hr2PP86+VfjtrFhrvjy7vNKu4b2zfy1SeFtyNhADgjrzXXRpuLvYim7tntX7LsKj4eXL4+/fP+iKK7j4jKo0GyIAz/bOk/wDpwt68c+EHxS8HeB/BI03xBqbW9+bh5jClu8hCkDByox29a2dZ+Nvg3xbcaPoOiT3s19d61pnll7YonyXsLnJPsp7VoqMnUU7dTOb1aPfaKKK9MxPCv2wrVr34daLbq4QvrUfzHoMW9wf6V8nR+Dp2BJn4HTCda+y/2kIRP4e8NRNjDa0OoyP+PS5rxFbNNrFoUBjGSXXBFctes4SshnksXhIOcLO7n0AFaEHgeMoWkkfA5JzjFenrY+W6vKIYU3ZyBnnscjtVlYYf3uyPGVwSTuGc9R9aweJl0A8wi8E2wJDrI+O4bFPTwnaI2BbK+OMNnNd/O0c6hEibzEXHIwBVSKW3UbmBZgvKqCBx/Okq02By3/CNWsWCbOJduMqUBJFbdpoEVriZViXZ82BEoP8AjWyskU8aqzlGbg4GcimGWONHhihCHHzPxjp0HOamVSTRcPiRS+Hmvtomoaij5a0voWhkHcEghSP896docBHizTGJ4SeMAD1rndEBm1WRd3C5P1rej1A6bqgvokSSS3kWRYm6OQfu8c8+1ZTh72m7R68Kitr0PY5XZHYBsHNZ2vEy6LfIWODCw9ulcxffE6xlVZE0meJiMkEMcH0zxVeT4hWWoW8unixulluF8tSE4Ge+c1yqhUWtjf6xSeikYHhmI/8ACXacqfN5ZLZHb5TXqDsx4yc5x9PauEEFz4YEWstYTSwchCV2hgR1BPBpT8TZSx26Vg9MNMo/kK2qU5VXeKMlVhSbUmdoXcZOGIHtUQknckrG4B7kVwz/ABOuMA/YbRCOxlYn9BVZ/idqLABbaxQH/fbH6iksNU7EPFUv5j0dI5mIO04x9amWOYYJQ/WvJZviZrP/ACze0VjzxCTx+LVVf4i65IMC+iQHPC26f1qvqlRi+uUkevi2n83cSMEZA3U9recqQrAHPc9K8Sk8d642FOrzoO4RUUD9Ko3Hi/WpT82rX7A88Tbf5VSwdR9US8dT6JnvotJsYdh9QKYbNwwZpVXnqf8A69fPEniC8kYma+vnPT57hjn9aqvqZOdzM5PUvIx/mapYKXch4+PSJ9FNJbxEie7gUjgkuo/rVeXVdJiY7tUtVI/6arz+tfPp1RGUK8MZ29iooXUsZ2BRzzgAVSwL7kvH9onvZ8VeH4eDqcTn/YJP8hUc3izRflZUuX/2lifn9K8Mj1hwOQAQOpxThrtw67Q+0AfxHg/Sn9RXcX9oT6I9Z1nxtpws2kNreCJThm8oNz271X0Pxwj7m0vTriRh3lZY8/rXlrXz3yLbzSRwITwQvX6mtvRt2npIGJkDj5Snb3pvCRSJ+vVGehax8XvEukwNJDo6SRL1dHVtn14/WuA8WfGPxB4s04affJDHZFw5UYPIOR2rUt78vn5GVBxvz0H49q5zxnpVjCtvd2SwiSWQRuI+FJ9cCnSo0ovWOpm8RUnuzu9HnEul6NJExQvHI439RggVP4tuIm8Kausp+Y2kuAuT8xjPXHGKpwxG10bR7faxdYGHyjJOWqrrPmp4b1lpACHtJRkdvkPasYRvK/mGL+JeiPqvx3n+3PA2P+gzJ/6b7ytsjgVyfxb1vTfDkvg7VdbultNPt9ZbzZmUkLusbtRwATySB+NcteftBfDq3OE1i4nP/TKzkP8AMCujF0pzmuVdDKnJJHqRX2Jpy9RmvFbn9pjwJCpENvrU5/2bdFB/N6x7j9qfw8ufs3hzVpfTzJY0/lmueOEqdinVR9B98Um3NfM93+1bGCfsfhEn082+/wAErKuP2q9aYH7N4Z0yP08yZ3/litFhKgvao7H9qRMvo2c/cb+dZPwpjI+C3jMFs/6UG57fIvFcD4i+JWqfEmxFxrFrZ2z2cmyJbYMFIIzzknmq+i+L9W0dj4ctpIhpOpxma4jMYLFgMDDdR0FV7NqLgdKacYs2vh+zj4leHlTAB1CLd9K+wXVtxwCa+Hrq+utMjutR0+Zre9tV82CZOqOOhFcvc/Fbx5cgiXxbq+D2W4KfyxTjQdVaMzrz5ZH6DeW5P3G/KkZdi5chB/tECvzhuvGPia6J+0+ItXkz13XshH86zptSv7o/v727mP8Atys38zV/Uu7MvbeR+kVxqenW+ftGpWMWP+elwi4/M1kXnjfwpZZ+1+J9Fi+t5Gf61+dy2txIflgmYn0QnNWI9H1OUgR6bePn+7Ax/pR9Tit5B7WXY+8Lj4t+ALfPmeLNNP8A1zZn/wDQVNZVx8dvhxbk/wDE+eU/9MrSU/8Asor4xh8J+IJv9XomoH/t3Yf0q7F4B8VTY2aFec/3lC/zNH1Wit2HNUeyPq+f9o/4fxZ8uTVp/wDrnaY/9CYVkXX7T3hJGP2fR9bm9yIk/wDZq+c4fhj4ulwP7JZM/wB+VB/WrsXwj8VSAE29omf71wv9KfssP1f4j5ar6Htdz+1NpQH+i+Frxj28y7Vf5Kaybj9qe5JP2XwlbqOxlvWP8lFebW/wZ8RyNiS50yP/ALbFv5Cr8PwR1FjibWbJD6JG7f4UWwqGqdZ9GdXN+1HrvP2fw5pUZPd5JH/qKybj9pjxpIf3NnosI/64O383qvB8DXIPm69Gcf3LY/1NXIvgfYIwFzrV0c/3IVH9TS9phUUqFd9DLm/aL+IMmdl3p0P/AFzsk4/PNZlx8dfiNNn/AIqKSIH/AJ5W8S/+y120HwW8OoR5t/qEn/AlX+lXo/hJ4TjUBorqQ/7dw39MUfWcOtl+A/qlZnlE/wAXPiBcZEnizVRn+5Ls/lisi78c+LLs/wCk+Jtaf1BvZMfzr3+3+Gvg2HH/ABKlc/7crn+tadv4I8IxECPQLEkd2j3fzNS8dSW0Slgaj6o+WJ9Y1O5/4+dSvJf9+4Zv5mqfzSN/E7H8TX2JDoegQH9zomnR45OLdeP0q5Hb2icwW1tGB/ciVcfkKl5iltEtZe+sj45g0q/uP9RYXUv+5Cx/pXZaTpeowadbrPp93GIgS26Fht5+lfUVtqU9pgh02egqO31xJ7tg235jzWFTMJPRROmhl8b6yPk3xFplzqGpefapvh8tVD54JA5rU+Guh3ln8SfCM06BUXWbInn1uEH9a+otW8B6Dr8Jmtx/Zt+efOgUbWP+0nQ/UYNcDP4M1Hw74q8OSXEHm2v9t6eBdQ8x83cXXupPvW+Hx0ajUOpwYnDzpyd1ofV1FFFemch5L+0c/l+H/DTbXYjWRgJ1z9kusV495yykNtVjwGAPXv3717B+0g8kfh7w20ON41kYz0/49LmvFoklaZ/tMGRgFiqcAn+lefi/j+QyZLgo+6OyLMThnQ8Y9AelNMpQKsmCW5VVOO/SlupDaP5UaeWPvFk644OMGoI4nDv824A7VOONuO9c6QxLjzZiFWRcMSFQ/e9yTWfcRLanIxlMdDwateayJgyxyRY++3GCf89KqXUErR7vNRR0JC4xVoBltPJgkMTH95j0K/7Iokuow3LDdk4BHJHf6VVAilLGF2kUdwCCfYVKbeaIsZo8HGMY5xjrmqshp2MDTpXs9RklaGR1O7YOnPqfatDxEgb5sBvnDDH8PepzDmSGVIz5keDwMjA9fwqtqlxHcwXKn5VaEsp7Oc9KtpNpnRTqc3MupzFzqErFwGAQnjJ6itrwJbrq3iKCO+lMdogyzZxuY8KAfrWGLJHUhieOao6fPd2epwvErILaVZQeucHIHuK3lHmi0jGjJRmnLY+gPiHaajeeDZNJu3EsemQmazdEIfcB0Y55+XIr5/W6dm+Z2x9a7fxX8Ttb161mtQsVnDKpUpACMkjByTzjviuMsbbyoFWRQ7Dqazw8Jwi/aG+LnSlJey2IzMTj5mPem7yRgBj3ya0AsZG7bg+vWlCKQCAD7jvW90cZn5x/AeD1pxLnICN9KvqF9BgD16UYxkKOncUXAzyshIxHkUohn2nauPwrSUcHC5zxz3NJKFKnknAGRnkUXAzPImbPTjvjNKbOQDkjHtWkI8DLZIxk49KQpkARHknoaLgZ4tMkKWwT7UrWaqcFvfNaHlSkk/ewOcdqUoHUh8nnOfU0XAomzi67ieO9OS1Rh8gPXODVvy1jX7nI9s8fSoZW5OEIAHUCi4CrGoBQqc+9aOl3ctq4KkPGBwjc81VUAr1IHBwamggkYFotrcZzmpfmM6ey1IXCuQsanr5ZArH8RGOVtOjRFQmfcVxg1XW3li+YMwbqDjpUrWNzPcRTS7ndMMh9ef5VlypMqMrPU7i8lw9ohJDJAAMA9c/p9ayNfnf+xNVjyW/0SU5Izj5Gz/Oo/OuryQC5ZYyihAydx9Kg1i3dPD+oyZVt1tL1Jzwh5rCEOW1zWvUVSd0e3ftpKX+F2kqoJY61FwP+uE9fG66feMMi3kx/u19w/tRQC58I+HomyQ2tLwPa1uTXhUekqsKyCFHBOCMECu6pVUHY5zxmPRdQkBZLWQr644qVNBvmx+7Vf95q9hfSVgbDpyRkFQcY9KgOnxs/J4YFgWHT8qz+sAeXL4WvSoLPEPoSami8JzsFL3USZ/2Ca9Sh0pBErIWLdweMAn9adZQLDK4Ks+w5XaoITnrz0qXiH0A5DSNJGk6Ndr55m811PMZXHXp616Hoeh6DqHw4l1gW4bXrJhEXLncqluwzjBB9KyPE0RjsgPK8sk42n61S8PXMsUU0MMvyTLtlUfxY5GfxrmqtzXMmeph2uVXF0hI7rX7OzuIEltZp0SVH+6VJ5Br1VfCfhqFn2aDpy46f6MP8K828MRZ8T6dtBLG6QcfWvbb+0lRjtVjjPU1zV6ji0kzqo01JNtGDHpWjwf6nS7ID2t0yP0qeKO1jfCWluoHdYlH9KlEcmTlMD6GlMEhU4TJ91NY8z6s15V2EMiIDsRV+gqB7j5+Py3VL9lc99p688Uw2pfG54w3sRQnYTRAbgDjA/A5oW6UMcFQP5UNZ46uA3sarrp6EnfOc9eKtWZDuiwbvcmFbipI5mx1Jz1NVlhiRtrM2OnfpUpazjJDXManH8TgfzNJpDUn1JZZSE+UkVBHLtYtvJ7ZzUc2oaPER52oWYXoc3Cf41UfxH4ZhGG1WwOOyy5x+QoUX2ByS6mjLOMk5bA54pouQwyGIXHTmsibxp4YjH/H9DJg4O1HbP6VUk+IHh2PPlNcOT022zf1qlTk+hDqRX2kdE7nOVJJ/ugU0Tk4HIbr0rl5PiRpgfCWd9IegxEo/Umq7/Ee2kYrHpU4PYtMi/wBDVKjPsS69NfaOyBYdWcnr0py7zw2/n0HWuBk+JdyrOItKjO0dWucj9BVV/iLqTL8sNhCeoGXf8+ar6vUfQl4mkup6hHG+0AozAe9DQzDBARV6fMea8nfxvrcx4urKIeqQ5A/Emmf8JLdyxfvtVnVhn/VogH8jR9VmL67TR6zLEojJkaJCB2auceNjdeZbscZzlVOK4E6pcXDZbULxkBG4+eFyPwxXKXuo3lxfyAajetAGICm4Y4H51ccJLqxfXYvZH07pOvwWkCreTgAD+70pdb8W6RfLpFhbXQkuZdZ0wKnHOL6Bj+gNeGWdrYGzhe4tlkd0GHcls+pOTUnh/wAP6dD488KahboYbhNaseF4WTNzGPu9uvalSwcFUUm9mZVsc5xcbH3HRRRXtHmnCfF3wtqvirSNJh0M2P2my1AXTLeyvGjJ5E0ZAZUc5zKD07GvNZPhZ46IAjXw2FzuKvqU7BsdP+XavoWis50YTd5ILnzhd/B7xrcyeYyeG95OWzqU5B9sfZ6F+D/jYQvGy+HSrEEAanOMf+S9fR9FT7Cn2C583/8ACnvG4ICL4aVMglf7Qmwcf9u1IPg9445P/FNbscH+0J8D8Ps9fSNFP2FPsO58zt8GPHbE/vPDQB5+W/nBz6/8e9L/AMKX8c55bw0fb+0J8fj/AKPX0vRR7GHYR8x3XwT8dTxeV5nhtYz1Av58n8fs9QzfAnxrLjLeGsBduDfz/wDyPX1FRT9jDsVGco3sfJ4/Z78bg8XPhrbnIH22f/4xUcn7O/jhySbvw1/4GT//ABivrSiq5USfIn/DOHjgNu+2+Gs/9fc//wAYqRf2dfHIUqbzw0QRj/j7n4/8gV9b0U+VAfJI/Z28cAAfa/DOAMf8fc//AMYpV/Z38cLjF14ZwO32yf8A+MV9a0UuVAfJy/s8+NQv+v8ADW48E/bZ+f8AyBTm/Z88bNgGbwyAMcC8nHT/ALYV9X0UcqA+TG/Z38bHP+keGsZzj7bP/wDGKR/2d/GrNk3Phvpg/wCmz/8AxivrSijlQHyWP2d/G4bP2rw37f6bP/8AGKVv2ePGxTH2jw2Cep+2z/8AxivrOijlQHyYn7PPjlSc3nhw9h/ps/A/78Uo/Z58bAf8fPhvPqb2f/4xX1lRRyoD5PX9nnxmGBebw24XoDfT/wDxinn9n3xlwVk8Ng4xkX8//wAj19W0UciA+Vh8AfGeMGTw0Rx/y/T/APyPQ3wB8achJPDSA+l9Pn/0nr6popckQPliL4DeOYzkXHhzOc/8f0+P/SerS/BDxuRiRvDL9s/b5wf/AEnr6dopeyj2A+aovgv41jjCgeG8jPP9oz//ACPSaj8F/G93pt3Zr/wjUSzxNGG/tCc7dylc/wDHvz16V9LUUvYwvew7nCfF7wtq3irSNJh0F7Fbqy1AXbC8laNGTyJoyAVRznMoPTsa80l+FPjeRWBi8NcnPGpTjB/8Bq+hqKcqUZu8kI+cp/hH46lUqR4ZAORkahPn8/s9RQfBzxtEF+Xw0zjgsdRn5/8AJevpKil7CHYD5xi+EfjtZHaT/hGXDc/8hCcEH6/Z6cPhJ45Qgwr4ZUgdDqM5Gff/AEevoyij2FPsFz5j1H4J+Or6JleXw0rMcki/nxn6fZ6h0v4FeNrBWAk8NSMxB3G/nHb/AK96+oqKPYwtaxaqSjsz5gX4IeOkleSOfw7HISCrJqE6lD6g/Z+tdbF4M+KX2ZI7m78OTygYaRtQnXd7kC3r3KiplhqUt0aLE1U7pngc3gL4nuDsm8Jqc9Wvbpv/AGlVWX4dfFZzlb3wgn/be4P84q+hqKX1Wl/KDxVV/aPm+T4X/Fd1I/tbwsuf7s0v/wAj1D/wqT4pkYbXdCH+5eSL/wC21fS1FUsPSX2SXXqP7R8xt8GviW+TJrWksT/1E5x/K3qpJ8CviJL/AKzVtGc++qXP/wAZr6noqlSgtkS6k3uz5Qf9n7xy+d134db/AHr+4P8A7RqEfs6+NcjdP4YYe93P/wDGK+taKfJHsTzM+Sh+zt42CgLP4WGO4upv/jFPH7Pfjsfdu/DAGMcXU/8A8Yr6yop8iC58kt+zx4+IONR8OAe13P8A/GKb/wAM7ePe+oeGz/29z/8AxivriijlQj5Gb9nTx4Qf+Jh4b5/6e5//AIxTR+zl49G3Go+HOD/z9z//ABivruinyoD5E/4Zy8d4wdQ8Nkf9fc//AMYo/wCGcfHef+Qh4bxjGPtc/wD8Yr67oo5UB8ir+zn48AAOo+Gz2/4+5/8A4xTR+zj475Dah4bKnt9rn/8AjFfXlFHKgPkM/s3+OM/8f3hvHYG8nP8A7Qq0v7O/jEIoL+GN4Ody3s4/9oV9ZUUuVDufLqfA3x6qhRc+Gwg6Bb6cf+0KveHfgp40svEOjXd7d6CbS01C2u5fLvJncrFMkhCgwAE4Xjkc96+lKKXs472C4UUUVYj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Start by lying on your stomach with your arm hanging straight down. Lift your arm&nbsp;to your side&nbsp;over&nbsp;a 2 second&nbsp;count until it is perpendicular with your torso, and then, slowly, lower your arm back to the starting position over a 4 second count. Repeat the movement 25 times&nbsp;to complete&nbsp;one set.&nbsp;Perform two sets on each side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9666=[""].join("\n");
var outline_f9_28_9666=null;
var title_f9_28_9667="Endoscopic classification of biliary atresia";
var content_f9_28_9667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Endoscopic classification of biliary atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Classification of biliary atresia according to appearance on endoscopic retrograde cholangiopancreatography (ERCP). In ERCP type 1, present in approximately 30 percent of patients, there is no visualization of the entire biliary tree. In ERCP type 2, present in approximately 50 percent of patients, there is visualization of the common bile duct and gallbladder, but not of the hepatic duct. In ERCP type 3, present in approximately 20 percent of patients, there is visualization of the common bile duct and gallbladder, with visualization of biliary lakes at the porta hepatis (type 3a) or of both hepatic ducts (type 3b). Improper positioning of the catheter during ERCP can lead to misclassification. Note that this ERCP classification of biliary atresia is different from the Kasai classification of biliary atresia, which is based on anatomy at operation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Guelrud M, Jaen D, Mendoza S, et al. ERCP in the diagnosis of extrahepatic biliary atresia. Gastrointest Endosc 1991; 37:522.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9667=[""].join("\n");
var outline_f9_28_9667=null;
var title_f9_28_9668="Besifloxacin: Patient drug information";
var content_f9_28_9668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Besifloxacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/4/16451?source=see_link\">",
"     see \"Besifloxacin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/3/7219?source=see_link\">",
"     see \"Besifloxacin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7804386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Besivance&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14944302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Besivance&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701614",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to besifloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696156",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Turn container upside down and shake once before each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12189 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-85BFFBD9BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9668=[""].join("\n");
var outline_f9_28_9668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7804386\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944302\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011392\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011391\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011396\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011397\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011399\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011394\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011395\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011400\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011401\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/4/16451?source=related_link\">",
"      Besifloxacin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/3/7219?source=related_link\">",
"      Besifloxacin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_28_9669="IPEX GI biopsy";
var content_f9_28_9669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    IPEX GI biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gastrointestinal biopsy from a patient with IPEX demonstrates villous atrophy and lymphocytic infiltrates of the bowel mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9669=[""].join("\n");
var outline_f9_28_9669=null;
var title_f9_28_9670="Orbital cellulitis photo";
var content_f9_28_9670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Orbital cellulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This young girl has erythema and edema in the&nbsp;preseptal area, which could be caused by either orbital or&nbsp;preseptal infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9670=[""].join("\n");
var outline_f9_28_9670=null;
var title_f9_28_9671="Acute cholangitis II - high power";
var content_f9_28_9671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute cholangitis (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are many neutrophils adjacent to and in a bile duct that is cut tangentially. Neutrophils in bile duct walls are often seen in acute bacterial cholangitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9671=[""].join("\n");
var outline_f9_28_9671=null;
var title_f9_28_9672="Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci";
var content_f9_28_9672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9672/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9672/contributors\">",
"     JoAnn M Tufariello, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9672/contributors\">",
"     Franklin D Lowy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9672/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9672/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9672/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9672/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/28/9672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulase-negative staphylococci are present on the skin of all humans and are the most frequent constituent of the normal flora at this site [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/1\">",
"     1",
"    </a>",
"    ]. Once considered relatively avirulent and usually a contaminant when isolated from a clinical specimen, these organisms have become increasingly recognized as agents of clinically-significant nosocomial bloodstream infections.",
"   </p>",
"   <p>",
"    Patients at risk include those with prosthetic valves, pacemakers, intravascular catheters or other foreign bodies in place, and immunocompromised hosts. Coagulase-negative staphylococci also account for significant morbidity and mortality in patients with native valve endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/2\">",
"     2",
"    </a>",
"    ]. These infections are inherently difficult to treat given the frequent presence of foreign material and the often multiple drug resistant nature of the organisms.",
"   </p>",
"   <p>",
"    The microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci will be reviewed here. The clinical features, diagnosis, and treatment of specific infections caused by these pathogens, including issues related to antimicrobial resistance, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5317?source=see_link\">",
"     \"Endocarditis due to coagulase-negative staphylococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23815?source=see_link\">",
"     \"Treatment of infections due to coagulase-negative staphylococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are 31 species currently recognized in the genus Staphylococcus, which are members of the Micrococcaceae family [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/3\">",
"     3",
"    </a>",
"    ]. Staphylococci are aerobic and facultatively anaerobic gram-positive cocci that have a tendency to form irregular clusters, produce catalase, are not motile, and do not form spores. Staphylococcus aureus and S. intermedius are the only coagulase-positive staphylococcal species.",
"   </p>",
"   <p>",
"    Although at least 18 species have been isolated from human skin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/4\">",
"     4",
"    </a>",
"    ], Staphylococcus epidermidis accounts for more than one-half of resident staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/5\">",
"     5",
"    </a>",
"    ] with extensive distribution over the body surface. In terms of clinical isolates, S. epidermidis is clearly predominant, comprising more than 75 percent of coagulase-negative staphylococci in clinical specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/6\">",
"     6",
"    </a>",
"    ]; this is perhaps due to its sheer numbers on the skin surface, although it may possess virulence determinants that other coagulase-negative staphylococci lack [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Other clinically-significant species include S. saprophyticus, which causes urinary tract infections in young adult women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/9\">",
"     9",
"    </a>",
"    ], whereas S. hominis, S. haemolyticus, S. warneri, and S. simulans have been more rarely isolated as pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/6\">",
"     6",
"    </a>",
"    ]. S. lugdunensis has increasingly been recognized as a cause of invasive infections that include endocarditis, osteomyelitis, and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12344?source=see_link\">",
"     \"Staphylococcus lugdunensis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Species identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Species identification of coagulase-negative staphylococci was originally approached based on a combination of morphologic assessment (colony size and pigmentation), biochemical and metabolic testing, and antibiotic susceptibility results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. These assays are employed in several commercial kits, which allow for rapid species and subspecies identification within several hours to one day, with an accuracy in the range of 70 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Although useful, commercial kits may at times lead to misidentification of species. This is due to the large number of species that must be distinguished, some variability in expression of biochemical phenotypes among the diverse non-S. epidermidis isolates, as well as potential ambiguity in interpreting colorimetric test results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Polymerase chain reaction (PCR)-based techniques have also been used for species identification of Staphylococcus epidermidis and a number of other clinically-important coagulase-negative staphylococcal species [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Some clinical microbiology labs do not routinely identify to the species level. In this case, the isolate should be identified simply as a coagulase-negative staphylococcus. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Identification beyond the level of species to actual strain delineation can be employed to address whether or not a particular isolate caused a true bacteremia, since coagulase-negative staphylococci are the most frequent blood culture isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], ubiquitous skin commensals, and also common contaminants. The rationale is that repetitive isolation of the same strain from an individual patient increases the probability of clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/23\">",
"     23",
"    </a>",
"    ]. Isolation of the same strain from more than one patient may also signal nosocomial transmission from a common source, such as patient-to-patient or staff-to-patient.",
"   </p>",
"   <p>",
"    In addition to biochemical testing, traditional strain typing methods have included antibiograms, phage typing, biofilm production, and plasmid profiling. More recently, various molecular techniques have come into use, including chromosomal analysis by ribotyping (based upon sequence differences in genes encoding rRNAs and flanking DNA), restriction fragment length polymorphism (RFLP) analysis, pulsed-field gel electrophoresis (allowing for resolution of large DNA fragments by restriction endonucleases that cleave DNA infrequently), PCR analysis of ribosomal DNA internal transcribed spacer regions (ITS-PCR), random amplified polymorphic DNA (RAPD) assays, and sequencing of genomic DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/3,6,11\">",
"     3,6,11",
"    </a>",
"    ]. These molecular techniques have increasingly been applied to strain identification. A multilocus sequence typing scheme has been developed for S. epidermidis that has demonstrated the diversity of the species. However, when these typing schemes were compared, it was felt that a combination of pulsed field gel electrophoresis and SCCmec typing were the most discriminatory [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/24\">",
"     24",
"    </a>",
"    ]. As a result of these typing studies, it has been demonstrated that there are clones that are extensively distributed across diverse geographic regions; these strains are all biofilm positive [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these newer molecular techniques are costly, time-consuming, require specially trained personnel, and are most suited to epidemiologic investigations. &nbsp;However, there have been efforts to automate some techniques to improve ease of performance and reliability, such as automated ribotyping [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the work on the pathogenesis of coagulase-negative staphylococcal infections derives from the observation that most infections with these organisms occur in the setting of foreign devices. These staphylococcal species, although less virulent than S. aureus, possess determinants that contribute to both colonization and infection. These include determinants that facilitate survival on skin surfaces, biofilm formation, adhesion to tissue and prosthetic surfaces, and components involved in immune evasion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/27\">",
"     27",
"    </a>",
"    ]. The surface molecule poly-gamma-DL-glutamic acid appears to play an important role in colonization of skin surfaces and immune evasion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prosthetic devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic devices are presumably inoculated with small numbers of coagulase-negative staphylococci at the time of implantation. The organisms may originate from the flora of the patient or surgical staff or from the environment. Intravascular catheters are colonized by skin flora that can either migrate down the external portion of the catheter tunnel or colonize the hub with catheter manipulations, thereby gaining access to the internal surface of the catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/6,29\">",
"     6,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biofilm that forms along the foreign body appears to facilitate infection by shielding these normally low virulence organisms from elimination by host defenses or antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/30\">",
"     30",
"    </a>",
"    ], perhaps through changes in bacterial metabolism, creation of a permeability barrier, or alterations in leukocyte function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. This association between foreign material and infection with coagulase-negative staphylococci has been confirmed in animal models. In one study, animals carrying subcutaneously implanted catheters developed infection at the catheter site in one-third of cases after injection of the organisms under their skin, whereas animals without the catheter did not become infected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Attachment, adherence, and slime production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The virulence factors that make coagulase-negative staphylococci especially adept at surviving on various biomaterials have been investigated. Bacterial adherence is believed to be the initial step in the pathogenesis of prosthetic device infection. Some of this initial rapid phase of attachment is thought to be mediated by nonspecific hydrophobic and van der Waals interactions. In addition, once introduced into the body, foreign materials quickly become coated with a layer of host proteins, including fibrinogen, fibronectin, and others, which serve as potential receptors for various staphylococcal surface proteins. Strains of S. epidermidis possess surface adhesins that are critical for interacting with these host proteins and mediating a more specific adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/11,34,35\">",
"     11,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once attachment occurs, an extracellular polysaccharide matrix or slime is elaborated, which encases the bacteria. This biofilm may function as a barrier to antibiotic penetration and may interfere with host defenses including T lymphocyte activation, opsonization, polymorphonuclear leukocyte migration, and macrophage function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Data from both animal studies and clinical investigations suggest that slime-producing strains of S. epidermidis exhibit greater virulence and disease causing potential in patients with prosthetic devices [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/33,36\">",
"     33,36",
"    </a>",
"    ], and that infections with slime-positive strains are more resistant to bacteriologic cure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/37\">",
"     37",
"    </a>",
"    ]. Experiments have shown that catecholamines, such as norepinephrine, promote both increased growth of the organisms and increased biofilm production on polystyrene and silicon, perhaps through increased acquisition of iron from transferrin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polysaccharide intercellular adhesin (PIA), a linear b-1,6-linked glucosaminoglycan, has been identified as a cell surface component, which mediates the intercellular adhesion of S. epidermidis, permitting cell clustering and the accumulation of a multilayered biofilm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/39\">",
"     39",
"    </a>",
"    ]. Production of PIA is controlled by genes in the intercellular adhesion (ica) operon, including both biosynthetic and regulatory elements [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. A variety of environmental stresses stimulate expression of the ica operon, including oxygen limitation, high temperature, osmotic stress, and sublethal concentrations of certain antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/40\">",
"     40",
"    </a>",
"    ], suggesting that biofilm formulation may represent an adaptation to hostile environmental conditions encountered within the host. In addition to slime (PIA) production, other potential virulence factors of coagulase-negative staphylococci include the various exoproteins: hemolysins, DNAse, protease, and fibrinolysin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISTINCTION OF TRUE BACTEREMIA FROM CONTAMINANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and microbiologic differentiation of true coagulase-negative staphylococcal bacteremia from pseudobacteremia or contamination remains a challenge, despite the evolving methods of species and strain identification described above. One study found a poor correlation between the presence of the same strain in multiple blood cultures as determined by pulsed-field gel electrophoresis and polymerase chain reaction and clinical definitions of true bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/42\">",
"     42",
"    </a>",
"    ]. Another study reached similar conclusions, finding that CoNS isolates were unrelated by pulsed-field gel electrophoresis in 15 of 38 episodes (39 percent) in which two or more blood cultures were positive within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/43\">",
"     43",
"    </a>",
"    ]. Speciation is of some help in differentiating between CoNS isolates from the same patient and has the advantage of being rapidly performed and readily available, even though the sensitivity and specificity are lower than for molecular typing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Concordant automated antibiotic susceptibility results have also been used to predict strain relatedness among CoNS blood culture isolates, and have been found to be highly predictive of genetic relatedness by pulsed-field gel analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/45\">",
"     45",
"    </a>",
"    ]. Of course, the assumption in these studies is that recovery of genetically identical CoNS isolates from multiple blood cultures represents true bacteremia, while recovery of genetically distinct isolates represents contamination. This is usually true but rarely this assumption may be incorrect in cases of repeated contamination with identical strains, or of true polyclonal infection with distinct strains [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Incidence of bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;National Nosocomial Infections Surveillance (NNIS) system data collected in medical intensive care units between 1992 and 1997 revealed that coagulase-negative staphylococci accounted for 36 percent of all bloodstream isolates, making these organisms the most common cause of nosocomial bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/46\">",
"     46",
"    </a>",
"    ]. Similarly, the NNIS survey conducted in neonatal intensive care units from 1986 to 1993 and in pediatric intensive care units from 1992 to 1997 found that coagulase-negative staphylococci accounted for 51 and 38 percent of bloodstream infections, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. A survey from the SCOPE (Surveillance and Control or Pathogens of Epidemiologic Importance) database of nosocomial bloodstream infections in United States hospitals from 1995 to 2002 also identified coagulase-negative staphylococci as the most common cause, accounting for 31 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/49\">",
"     49",
"    </a>",
"    ]. Increased use of intravascular devices is an important contributor to bloodstream infections with these organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the frequency of isolation of coagulase-negative staphylococci, only 4 to 12 percent of patients with blood cultures positive for these organisms are estimated to have significant bloodstream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. A number of clinical and microbiologic factors have been postulated to signify true bacteremia. The clinical features include fever, hypotension, leukocytosis, and disseminated intravascular coagulation. The microbiologic factors include growth in culture within 48 hours, growth in both aerobic and anaerobic bottles, and multiple cultures (two or more blood culture sets) positive for the same organism with identical antibiograms. Slime production by the isolate, assayed by the ability of the bacteria to adhere to plastic material, also may be useful for predicting true bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/52\">",
"     52",
"    </a>",
"    ]. Isolation of other skin contaminants and growth of organisms in blood drawn for culture while receiving effective antimicrobial therapy have been used as indicators of contamination.",
"   </p>",
"   <p>",
"    Several series of positive blood cultures have estimated a higher proportion of true bacteremias caused by coagulase-negative staphylococci.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 227 blood cultures positive for coagulase-negative staphylococci, 26 percent were judged to be true bacteremias [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/53\">",
"       53",
"      </a>",
"      ]. This value is two to four times higher than previous reports, which may be due to the fact that the study population consisted of individuals at potentially higher risk than a general hospital population, such as bone marrow transplant recipients, patients with hematologic malignancy, and those in intensive care units. Seventeen percent of bloodstream infections were polymicrobial, and 10 percent were caused by species other than S. epidermidis in this study.",
"     </li>",
"     <li>",
"      In one neonatal study assessing the clinical significance of positive blood cultures for coagulase-negative staphylococci, 25 of 59 (42 percent) were considered true infections [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/54\">",
"       54",
"      </a>",
"      ]. Cultures from infected infants yielded higher concentrations of organisms than did those cultures that represented probable contamination. Infants with true bacteremia also were more likely to have a central intravenous catheter and to have received any parenteral nutrition or lipids.",
"     </li>",
"     <li>",
"      In another cohort study of more than 3000 blood cultures from 1433 patients, 89 were positive for skin flora, of which 91 percent were coagulase-negative staphylococci [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/21\">",
"       21",
"      </a>",
"      ]. The incidence of significant bacteremia due to coagulase-negative staphylococci was estimated at 25 percent in this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This latter report also addressed the issue of potential misuse of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    therapy. There was an excellent correlation in this study between the initial clinical impression of the attending physicians and retrospective analysis by independent reviewers about whether the blood culture represented a significant bloodstream infection or contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/21\">",
"     21",
"    </a>",
"    ]. Nevertheless, the physicians still used antibiotics to treat nearly one-half of the patients with contaminated blood cultures, leading to vancomycin misuse in 34 percent of patients. Other studies have also found costs attributed to the unnecessary use of vancomycin to be greater than $4000 per patient [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/55\">",
"     55",
"    </a>",
"    ] and costs of more than $5000 per patient for overall inappropriate antimicrobial use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9672/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Colonization with resistant organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, more than 80 percent of coagulase-negative staphylococcal isolates are resistant to methicillin and semisynthetic penicillins. They are also frequently resistant to multiple other antibiotic families. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23815?source=see_link\">",
"     \"Treatment of infections due to coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H319737883\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coagulase-negative staphylococci are present on the skin of all humans and are the most frequent constituent of the normal flora at this site. Once considered relatively avirulent and usually a contaminant when isolated from a clinical specimen, these organisms have become increasingly recognized as agents of clinically significant nosocomial bloodstream infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients at risk include those with prosthetic valves, pacemakers, intravascular catheters or other foreign bodies in place, and immunocompromised hosts. These infections are inherently difficult to treat given the frequent presence of foreign material and the often multiple drug-resistant nature of the organisms. Coagulase-negative staphylococci also account for significant morbidity and mortality in patients with native valve endocarditis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are more than 30 species currently recognized in the genus Staphylococcus, which are members of the Micrococcaceae family. Staphylococci are aerobic and facultatively anaerobic gram-positive cocci that have a tendency to form irregular clusters, produce catalase, are not motile, and do not form spores. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although at least 18 species have been isolated from human skin, Staphylococcus epidermidis accounts for more than one-half of resident staphylococci with extensive distribution over the body surface. In terms of clinical isolates, S. epidermidis is clearly predominant, comprising more than 75 percent of coagulase-negative staphylococci in clinical specimens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Species identification of coagulase-negative staphylococci can be made using conventional methods, such as colony morphology (size and pigment), enzymatic activities, such as alkaline phosphatase, urease, ornithine decarboxylase, b-glucosidase, and b-galactosidase; acid production from various sugars, including maltose, sucrose, d-mannitol, d-trehalose, and others; and susceptibility to novobiocin. Some clinical microbiology labs do not routinely identify to the species level. In this case, the isolate should be identified simply as a coagulase-negative staphylococcus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Species identification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most infections with these coagulase-negative staphylococci occur in the setting of foreign devices. The exception to this is S. lugdunensis, which appears capable of causing more invasive infections. These staphylococcal species, although less virulent than S. aureus, possess determinants that contribute to both colonization and infection. These include determinants that facilitate survival on skin surfaces, biofilm formation, adhesion to tissue and prosthetic surfaces, and components involved in immune evasion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prosthetic devices are presumably inoculated with small numbers of coagulase-negative staphylococci at the time of implantation. The organisms may originate from the flora of the patient or surgical staff or from the environment. Intravascular catheters are colonized by skin flora that can either migrate down the external portion of the catheter tunnel or colonize the hub with catheter manipulations, thereby gaining access to the internal surface of the catheter. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prosthetic devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The biofilm that forms along the foreign body appears to facilitate infection by shielding these normally low virulence organisms from elimination by host defenses or antimicrobial therapy, perhaps through changes in bacterial metabolism, creation of a permeability barrier, or alterations in leukocyte function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prosthetic devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical and microbiologic differentiation of true coagulase-negative staphylococcal bacteremia from pseudobacteremia or contamination remains a challenge. A number of clinical and microbiologic factors have been postulated to signify true bacteremia. The clinical features include fever, hypotension, leukocytosis, and disseminated intravascular coagulation. The microbiologic factors include growth in culture within 48 hours, growth in both aerobic and anaerobic bottles, and multiple cultures (two or more blood culture sets) positive for the same organism with identical antibiograms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Distinction of true bacteremia from contaminants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/1\">",
"      Roth RR, James WD. Microbial ecology of the skin. Annu Rev Microbiol 1988; 42:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/2\">",
"      Chu VH, Woods CW, Miro JM, et al. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis 2008; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/3\">",
"      Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev 1994; 7:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/4\">",
"      Hamory BH, Parisi JT, Hutton JP. Staphylococcus epidermidis: a significant nosocomial pathogen. Am J Infect Control 1987; 15:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/5\">",
"      Leeming JP, Holland KT, Cunliffe WJ. The microbial ecology of pilosebaceous units isolated from human skin. J Gen Microbiol 1984; 130:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/6\">",
"      Pfaller MA, Herwaldt LA. Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci. Clin Microbiol Rev 1988; 1:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/7\">",
"      Gemmell, CG. Virulence characteristics of Staphylococcus epidermidis. J Med Microbiol 1986; 22:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/8\">",
"      Males BM, Rogers WA Jr, Parisi JT. Virulence factors of biotypes of Staphylococcus epidermidis from clinical sources. J Clin Microbiol 1975; 1:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/9\">",
"      Wallmark G, Arremark I, Telander B. Staphylococcus saprophyticus: a frequent cause of acute urinary tract infection among female outpatients. J Infect Dis 1978; 138:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/10\">",
"      Ebright JR, Penugonda N, Brown W. Clinical experience with Staphylococcus lugdunensis bacteremia: a retrospective analysis. Diagn Microbiol Infect Dis 2004; 48:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/11\">",
"      Rogers KL, Fey PD, Rupp ME. Coagulase-negative staphylococcal infections. Infect Dis Clin North Am 2009; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/12\">",
"      Baird-Parker AC. Staphylococci and their classification. Ann N Y Acad Sci 1965; 128:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/13\">",
"      Kloos WE, Schleifer KH. Simplified scheme for routine identification of human Staphylococcus species. J Clin Microbiol 1975; 1:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/14\">",
"      Gemmell CG, Dawson JE. Identification of coagulase-negative staphylococci with the API staph system. J Clin Microbiol 1982; 16:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/15\">",
"      Kloos WE, Wolfshohl JF. Identification of Staphylococcus species with the API STAPH-IDENT system. J Clin Microbiol 1982; 16:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/16\">",
"      Hussain Z, Stoakes L, Stevens DL, et al. Comparison of the MicroScan system with the API Staph-Ident system for species identification of coagulase-negative staphylococci. J Clin Microbiol 1986; 23:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/17\">",
"      Bannerman TL, Kleeman KT, Kloos WE. Evaluation of the Vitek Systems Gram-Positive Identification card for species identification of coagulase-negative staphylococci. J Clin Microbiol 1993; 31:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/18\">",
"      Carretto E, Barbarini D, Couto I, et al. Identification of coagulase-negative staphylococci other than Staphylococcus epidermidis by automated ribotyping. Clin Microbiol Infect 2005; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/19\">",
"      Gribaldo S, Cookson B, Saunders N, et al. Rapid identification by specific PCR of coagulase-negative staphylococcal species important in hospital infection. J Med Microbiol 1997; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/20\">",
"      Martineau F, Picard FJ, Roy PH, et al. Species-specific and ubiquitous DNA-based assays for rapid identification of Staphylococcus epidermidis. J Clin Microbiol 1996; 34:2888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/21\">",
"      Souvenir D, Anderson DE Jr, Palpant S, et al. Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. J Clin Microbiol 1998; 36:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/22\">",
"      Khatib R, Riederer KM, Clark JA, et al. Coagulase-negative staphylococci in multiple blood cultures: strain relatedness and determinants of same-strain bacteremia. J Clin Microbiol 1995; 33:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/23\">",
"      Christensen GD, Bisno AL, Parisi JT, et al. Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis. Ann Intern Med 1982; 96:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/24\">",
"      Miragaia M, Carri&ccedil;o JA, Thomas JC, et al. Comparison of molecular typing methods for characterization of Staphylococcus epidermidis: proposal for clone definition. J Clin Microbiol 2008; 46:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/25\">",
"      Miragaia M, Thomas JC, Couto I, et al. Inferring a population structure for Staphylococcus epidermidis from multilocus sequence typing data. J Bacteriol 2007; 189:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/26\">",
"      Gordon RJ, Miragaia M, Weinberg AD, et al. Staphylococcus epidermidis colonization is highly clonal across US cardiac centers. J Infect Dis 2012; 205:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/27\">",
"      Otto M. Staphylococcus epidermidis--the 'accidental' pathogen. Nat Rev Microbiol 2009; 7:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/28\">",
"      Kocianova S, Vuong C, Yao Y, et al. Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest 2005; 115:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/29\">",
"      von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis 2002; 2:677.",
"     </a>",
"    </li>",
"    <li>",
"     Worms, R, Roujeau, J, Du Buit, H. The effect of a foreign body on the histological response to staphylococcal infection. In: Contributions to Microbiology and Immunology (Vol 1), Staphylococci and Staphylococcal Infections. Jeljaszewicz, J (Ed), Karger, Basel 1973. p.258.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/31\">",
"      McDERMOTT W. Microbial persistence. Yale J Biol Med 1958; 30:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/32\">",
"      Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982; 146:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/33\">",
"      Christensen GD, Simpson WA, Bisno AL, Beachey EH. Experimental foreign body infections in mice challenged with slime-producing Staphylococcus epidermidis. Infect Immun 1983; 40:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/34\">",
"      Bowden MG, Chen W, Singvall J, et al. Identification and preliminary characterization of cell-wall-anchored proteins of Staphylococcus epidermidis. Microbiology 2005; 151:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/35\">",
"      Herrmann M, Vaudaux PE, Pittet D, et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J Infect Dis 1988; 158:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/36\">",
"      Ishak MA, Gr&ouml;schel DH, Mandell GL, Wenzel RP. Association of slime with pathogenicity of coagulase-negative staphylococci causing nosocomial septicemia. J Clin Microbiol 1985; 22:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/37\">",
"      Davenport DS, Massanari RM, Pfaller MA, et al. Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. J Infect Dis 1986; 153:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/38\">",
"      Lyte M, Freestone PP, Neal CP, et al. Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes. Lancet 2003; 361:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/39\">",
"      Mack D, Fischer W, Krokotsch A, et al. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis. J Bacteriol 1996; 178:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/40\">",
"      G&ouml;tz F. Staphylococcus and biofilms. Mol Microbiol 2002; 43:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/41\">",
"      Heilmann C, Schweitzer O, Gerke C, et al. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis. Mol Microbiol 1996; 20:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/42\">",
"      Seo SK, Venkataraman L, DeGirolami PC, Samore MH. Molecular typing of coagulase-negative staphylococci from blood cultures does not correlate with clinical criteria for true bacteremia. Am J Med 2000; 109:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/43\">",
"      Seybold U, Reichardt C, Halvosa JS, Blumberg HM. Clonal diversity in episodes with multiple coagulase-negative Staphylococcus bloodstream isolates suggesting frequent contamination. Infection 2009; 37:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/44\">",
"      Al Wohoush I, Rivera J, Cairo J, et al. Comparing clinical and microbiological methods for the diagnosis of true bacteraemia among patients with multiple blood cultures positive for coagulase-negative staphylococci. Clin Microbiol Infect 2011; 17:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/45\">",
"      Camerer A, Kohlenberg A, Stefanik D, Seifert H. Evaluation of quantitative antibiotic susceptibility testing by Vitek 2 as a routine method to predict strain relatedness of coagulase-negative staphylococci isolated from blood cultures. J Clin Microbiol 2011; 49:3355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/46\">",
"      Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/47\">",
"      Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1996; 98:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/48\">",
"      Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103:e39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/49\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/50\">",
"      Kirchhoff LV, Sheagren JN. Epidemiology and clinical significance of blood cultures positive for coagulase-negative staphylococcus. Infect Control 1985; 6:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/51\">",
"      Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/52\">",
"      Garc&iacute;a P, Ben&iacute;tez R, Lam M, et al. Coagulase-negative staphylococci: clinical, microbiological and molecular features to predict true bacteraemia. J Med Microbiol 2004; 53:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/53\">",
"      Herwaldt LA, Geiss M, Kao C, Pfaller MA. The positive predictive value of isolating coagulase-negative staphylococci from blood cultures. Clin Infect Dis 1996; 22:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/54\">",
"      Nataro JP, Corcoran L, Zirin S, et al. Prospective analysis of coagulase-negative staphylococcal infection in hospitalized infants. J Pediatr 1994; 125:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/55\">",
"      Bates DW, Cook EF, Goldman L, Lee TH. Predicting bacteremia in hospitalized patients. A prospectively validated model. Ann Intern Med 1990; 113:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9672/abstract/56\">",
"      Dunagan WC, Woodward RS, Medoff G, et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med 1989; 87:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3158 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9672=[""].join("\n");
var outline_f9_28_9672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H319737883\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Species identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prosthetic devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Attachment, adherence, and slime production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISTINCTION OF TRUE BACTEREMIA FROM CONTAMINANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Incidence of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Colonization with resistant organisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H319737883\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5317?source=related_link\">",
"      Endocarditis due to coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12344?source=related_link\">",
"      Staphylococcus lugdunensis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23815?source=related_link\">",
"      Treatment of infections due to coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_28_9673="Definition and pathogenesis of ischemic preconditioning";
var content_f9_28_9673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"23\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and pathogenesis of ischemic preconditioning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9673/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9673/contributors\">",
"     Derek J Hausenloy, MD, PhD, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9673/contributors\">",
"     Derek M Yellon, PhD, DSc, Hon FRCP, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9673/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9673/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/28/9673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myocardium possesses innate physiologic adaptive processes that render it more resistant to potentially lethal ischemic injury. A number of these adaptive mechanisms have been identified; one is the phenomenon of ischemic preconditioning which provides the myocardium with the most powerful means of delaying myocardial infarction that has been identified. Ischemic preconditioning refers to the protection conferred to ischemic myocardium by preceding brief periods of sublethal ischemia.",
"   </p>",
"   <p>",
"    Other protective mechanisms include the long-term development of coronary collateral vessels, myocardial hibernation and stunning and ischemic postconditioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=see_link\">",
"     \"Coronary collateral circulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=see_link&amp;anchor=H26#H26\">",
"     \"Ischemic reperfusion injury of the heart\", section on 'Ischemic postconditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition and pathogenesis of ischemic preconditioning will be reviewed here. The evidence for existence and clinical implications of these phenomena in the human myocardium and possible future therapeutic applications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISCHEMIC PRECONDITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic preconditioning was originally described by Murry and coworkers as the protection conferred to ischemic myocardium by preceding brief periods of sublethal ischemia separated by periods of reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/1\">",
"     1",
"    </a>",
"    ]. In this report, four five-minute episodes of regional ischemia in the canine myocardium, each followed by a five-minute period of reperfusion, resulted in preservation of high energy phosphates, and significantly delayed or protected against myocardial necrosis during a subsequent prolonged period of ischemia. The net effect was a 75 percent reduction in infarct size compared to a control group of dogs.",
"   </p>",
"   <p>",
"    Since this original study, ischemic preconditioning has been reproducibly demonstrated in all animal species studied including rabbits, rats, mice, and pigs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. There is also evidence that the human myocardium can be preconditioned and that ischemic preconditioning may occur as part of some naturally occurring ischemic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, in addition to enhanced tolerance to lethal cell injury, preconditioning is protective against other end-points of ischemia-reperfusion injury including postischemic contractile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/7\">",
"     7",
"    </a>",
"    ], and ischemia- and reperfusion-induced ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Ischemic preconditioning also decreases apoptosis in animals, another mechanism that can contribute to cell death after myocardial ischemia and reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction in infarction size resulting from ischemic preconditioning is a graded phenomenon. In one animal study, ischemia lasting less than two minutes did not reduce infarct size, even when there were multiple cycles of ischemia; in contrast, infarct size was significantly and progressively reduced by a single ischemic episode lasting three or ten minutes (infarct size 17 percent without ischemic preconditioning versus 9 and 2 percent with three and ten minutes of ischemic preconditioning, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protection afforded by ischemic preconditioning is apparent immediately after the preconditioning ischemia, but is short lived and wanes after one to two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. After 12 to 24 hours following the preconditioning ischemia, a delayed phase of myocardial protection is induced which, although not as powerful as the early phase, is more prolonged and lasts up to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. This delayed phase of resistance to ischemic injury has been termed the \"second window of protection\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/17\">",
"     17",
"    </a>",
"    ] distinguishing it from early or \"classic\" preconditioning.",
"   </p>",
"   <p>",
"    Most laboratory studies of ischemic preconditioning have been performed in animals with \"normal\" hearts; these observations do not necessarily permit conclusions about the influence of coexisting pathology. More recent experiments have shown that hypertrophied myocardium is amenable to preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], while the effect of age is uncertain. Some reports have found that the preconditioning response is conserved in senescent myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/20\">",
"     20",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, the demonstration of cardioprotection by preconditioning in the clinical setting suggests that patients with ischemic heart disease are amenable to preconditioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Duration of ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A threshold must be reached during preconditioning ischemia to achieve protection during prolonged ischemia. In one study in rabbit myocardium, for example, preconditioning with two minutes of ischemia was insufficient to confer protection whereas three to five minutes of ischemia resulted in a significant reduction in infarct size [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/23\">",
"     23",
"    </a>",
"    ]. When the two minute preconditioning ischemia was repeated two times, infarct size was limited to the same level as a single episode of five minutes of preconditioning; however, potentiation of the protective effect by repetition was not observed when the duration of the preconditioning ischemia was five minutes. In other studies, extending the duration of preconditioning ischemia beyond 10 minutes abolished the protection or even has deleterious consequences during the prolonged ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms underlying ischemic preconditioning have not been completely elucidated (",
"    <a class=\"graphic graphic_algorithm graphicRef71019 \" href=\"UTD.htm?11/5/11347\">",
"     algorithm 1",
"    </a>",
"    ). A number of early theories for the preconditioning effect have been thoroughly investigated and ruled out. As examples, the protection conferred by ischemic preconditioning is not due to recruitment of collateral vessels during the prolonged ischemic insult [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/1,2,5,26,27\">",
"     1,2,5,26,27",
"    </a>",
"    ] or to myocardial stunning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been hypothesized that glycogen depletion occurs during the preconditioning episodes and that the lower glycogen levels during prolonged ischemia contribute to the attenuation of ischemic acidosis which is observed in preconditioned hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. However, one animal study found that, although preischemic glycogen levels did influence the extent of ischemic acidosis, they were not the sole determinants of acidosis or of postischemic functional or metabolic recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In recent years, considerable progress has been made toward the identification of potential cell triggers, intracellular signaling cascades, and end-effectors involved in ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. There are several lines of evidence suggesting a role for endogenous paracrine mediators, released during the brief period of ischemia and acting on local receptors, as triggers of ischemic preconditioning. Various models of preconditioning in different species have implicated the involvement of substances such as adenosine&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/2\">",
"     2",
"    </a>",
"    ], acetylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/33\">",
"     33",
"    </a>",
"    ], catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/34\">",
"     34",
"    </a>",
"    ], angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/35\">",
"     35",
"    </a>",
"    ], bradykinin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/36\">",
"     36",
"    </a>",
"    ], endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/37\">",
"     37",
"    </a>",
"    ], opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/38\">",
"     38",
"    </a>",
"    ], and reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative importance of the mediators may vary with the duration of preconditioning ischemia and timing. In one study, for example, bradykinin was essential when preconditioning ischemia lasted for three minutes while adenosine is more important during preconditioning ischemia lasting ten minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There also appears to be an additive interaction of individual preconditioning triggers to achieve the protective threshold. This was illustrated in a report using human atrial muscle in which two individual triggers (a subthreshold hypoxic insult and elevated bradykinin levels by ACE inhibition) were insufficient to induce preconditioning when administered separately but, in combination, produced a full protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Timing of activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to the time at which mediators of ischemic preconditioning act, mediators such as adenosine and protein kinase C are released or activated in response to the preconditioning stimulus and therefore act prior to or during the index ischemic period. In contrast, reactive oxygen species and prosurvival kinases act both prior to the index ischemic period and at the time of reperfusion after the index ischemic period, while inhibition of opening of the mitochondrial permeability transition pores occurs only during reperfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative importance of the triggers implicated in preconditioning seems to be dependent upon the species and the end point of ischemia-reperfusion injury studied. Adenosine, an endogenous compound formed from the breakdown of adenosine triphosphate (ATP) in myocytes during periods of ischemia has been consistently shown to be involved in triggering preconditioning in most animal species studied, including humans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/41\">",
"     41",
"    </a>",
"    ]. An inability to produce adenosine endogenously is associated with refractoriness of the myocardium to ischemic preconditioning while stimulation of myocardial adenosine A1 receptors by an exogenously administered agonist reinduces cardioprotection of preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/42\">",
"     42",
"    </a>",
"    ]. Furthermore, the myocardium can be maintained in a preconditioned state against ischemia-reperfusion by repeated activation of the adenosine A1 receptor over a 10 day period, without the development of tachyphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Protein kinase C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of these triggers such as adenosine, norepinephrine, acetylcholine, and bradykinin are coupled to pertussis toxin sensitive inhibitory G-proteins (Gi). It has been proposed that activation of these Gi-protein coupled receptors by various ligands results in activation of a number of kinase cascades at the center of which lies protein kinase C (PKC) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One animal study reported that a small increase in intracellular calcium concentration which results from myocardial ischemia and reperfusion can also activate PKC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/45\">",
"     45",
"    </a>",
"    ]. In another report, a brief intracoronary infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    mimicked infarct size reduction seen with preconditioning; this effect could be blocked by an inhibitor of calcium influx [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/46\">",
"     46",
"    </a>",
"    ]. Activation of PKC can occur by alpha adrenoreceptor stimulation during ischemic preconditioning and this also requires calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/47\">",
"     47",
"    </a>",
"    ]. This group of enzymes is therefore thought to be an important intermediate in the signal transduction pathway of ischemic preconditioning, resulting in phosphorylation and activation of possible end-effector(s).",
"   </p>",
"   <p>",
"    A number of subsequent studies supported this hypothesis. Ischemic preconditioning is blocked by pretreatment with specific PKC inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/47,48\">",
"     47,48",
"    </a>",
"    ] and the substitution of preconditioning ischemia with PKC activators mimics the infarct-limiting effects of ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/48\">",
"     48",
"    </a>",
"    ]. The time course of classic preconditioning also parallels the transient translocation of PKC to the sarcolemmal membrane following activation which lasts for about 60 minutes. Which PKC isoenzyme(s) are activated during preconditioning ischemia is not known.",
"   </p>",
"   <p>",
"    It is also likely that other protein kinases, in parallel with or following activation by PKC, may play a role in classic ischemic preconditioning. Activation of tyrosine protein kinases may be a crucial step in the signaling cascade since genistein, a selective tyrosine kinase inhibitor, abolishes the protective effects of preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/49\">",
"     49",
"    </a>",
"    ]. Protein kinase A has also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/50\">",
"     50",
"    </a>",
"    ]. The relative positions of PKC, tyrosine kinase, and other kinases in the signal transduction pathway of ischemic preconditioning are currently under investigation. Tyrosine kinase may be downstream of PKC and tyrosine phosphorylation may activate a member of the mitogen activated protein kinase (MAPK) family [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/49,51\">",
"     49,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ATP-dependent potassium channels",
"    </span>",
"    &nbsp;&mdash;&nbsp;ATP dependent potassium channels (KATP) appear to be involved in the metabolic adaptation to ischemia seen during preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/52\">",
"     52",
"    </a>",
"    ]. There is evidence that mitochondrial KATP channels rather than surface sarcolemmal KATP channels are the likely effectors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Opening of these channels results in a repolarizing current that reduces the duration of the cardiac action potential, leading to reduced calcium entry into the myocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/55\">",
"     55",
"    </a>",
"    ]. This results in a reduction in cardiac workload, an enhancement of myocardial viability, and a reduction in cardiac sympathetic nerve injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential importance of these channels can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an experimental model, the transfer of cardiac KATP channel subunits to KATP channel-deficient cells resulted in protection from hypoxia-reoxygenation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dysfunction of the mitochondrial KATP channel may be responsible for the failure to precondition the diabetic heart [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The KATP channels may interact with the other mediators described above. Protein kinase C activates these channels in human and rabbit ventricular myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/59\">",
"     59",
"    </a>",
"    ], and there may be synergistic action of adenosine and PKC on KATP channels and shortening of action potential duration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .) Further support for the interaction between these factors comes from one study that found that adenosine receptor activation primes the opening of mitochondrial KATP channels in a protein kinase C-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Opioid receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activation of delta opioid receptors within cardiac myocytes triggers ischemic preconditioning in animal models and in human atrial tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/62\">",
"     62",
"    </a>",
"    ]; their stimulation mimics ischemic preconditioning while their blockade abolishes it [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. The opioid receptors are coupled to G proteins and can activate PKC and mitochondrial KATP channels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Reactive oxygen species",
"    </span>",
"    &nbsp;&mdash;&nbsp;In response to a preconditioning stimulus, the mitochondrial production of reactive oxygen species (ROS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/67\">",
"     67",
"    </a>",
"    ], prior to the index ischemic period, acts as a mediator of the preconditioning signal through the activation of various protein kinases such as PKC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/39\">",
"     39",
"    </a>",
"    ], extracellular-signal regulated kinases",
"    <span class=\"nowrap\">",
"     (Erk1/2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/68\">",
"     68",
"    </a>",
"    ], and p38 MAPK [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/49,69\">",
"     49,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrated the importance of ROS in preconditioning:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The preconditioning stimulus can induce mitochondrial release of ROS [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exogenous ROS can mimic the protective effect of ischemic preconditioning [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The presence of an antioxidant during the preconditioning phase can diminish the degree of protection [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/39,71\">",
"       39,71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, reducing oxidative stress normally generated during reperfusion may be protective [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Prosurvival kinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signaling through the prosurvival, phosphatidyl inositol 3-OH kinase (PI3K)-Akt cascade [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/73-75\">",
"     73-75",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     ERK1/2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/76,77\">",
"     76,77",
"    </a>",
"    ] during the preconditioning phase appears to contribute to the protective effect of ischemic preconditioning. Signaling through this pathway then results in the activation of endothelial nitric oxide synthase (eNOS), opening of the mitochondrial KATP channel [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/78\">",
"     78",
"    </a>",
"    ], and cardioprotection due to the mitochondrial generation of reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prosurvival kinases also appear to contribute to protection at the time of reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/76\">",
"     76",
"    </a>",
"    ], acting in part by inhibition of mitochondrial permeability transition pore (MPTP) opening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Inhibition of MPTP opening",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that a common pathway for ischemic preconditioning, PKC activation, and mitochondrial KATP channel opening to protect the myocardium occurs via inhibition of mitochondrial permeability transition pore (MPTP) opening during reperfusion, thereby preventing uncoupling of the mitochondria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. The MPTP is a nonspecific channel of the inner mitochondrial membrane that opens during the first few minutes of postischemic reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/81\">",
"     81",
"    </a>",
"    ], and is a critical determinant of both apoptotic and necrotic cell death in the setting of ischemia-reperfusion injury [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/82\">",
"     82",
"    </a>",
"    ]. Inhibition of MPTP opening with ischemic preconditioning is mediated by activation of the prosurvival kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Second window of protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triggers and signaling pathways mentioned above have also been implicated in the delayed phase (second window) of ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/17\">",
"     17",
"    </a>",
"    ]. In animals, preconditioning induces late protective effects against endothelial injury after ischemia and reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with classic preconditioning, the specific triggers and mediators involved depend upon the species and the end-points studied. As an example, adenosine is an important trigger for the delayed protection against myocardial infarction in the rabbit and rat [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. In a study in rats, adenosine A1 receptor activation induced delayed myocardial protection, mediated by the mitochondrial antioxidant manganese superoxide dismutase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, delayed preconditioning against stunning, originally described in the pig heart, involves free radicals and increased formation of nitric oxide via the inducible form of nitric oxide synthetase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/86,87\">",
"     86,87",
"    </a>",
"    ], but not adenosine&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Nitric oxide directly activates the mitochondrial, but not sarcolemmal KATP channels; this provides a link between nitric oxide-induced cardioprotection and the KATP channels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/90\">",
"     90",
"    </a>",
"    ]. The delayed antiarrhythmic effect following preconditioning in the canine myocardium is abolished by pretreatment by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , an effect that may be due to inhibition of nitric oxide or products of the cyclooxygenase pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evidence for a role of the cyclooxygenase pathway in the second window of protection comes from studies in rabbits showing that delayed ischemic preconditioning induces upregulation of cyclooxygenase-2 (COX-2), leading to increased prostaglandin synthesis in the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]; COX-2 upregulation may be mediated by nitric oxide&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/94\">",
"     94",
"    </a>",
"    ]. Administration of selective COX-2 inhibitors in this rabbit model abolishes both the increase in tissue prostaglandins and the cardioprotective effects of ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]; this observation has implications for the use of COX-2 inhibitor therapy in patients with ischemic heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical implications of ischemic preconditioning\", section on 'Therapeutic applications of preconditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     REMOTE ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has emphasized the importance of local factors in ischemic preconditioning. However, systemic factors also may be important since localized ischemia can protect distant sites during subsequent ischemia. In animal models, ischemia of the lower limb reduced subsequent myocardial infarction size after coronary occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings may be applicable to humans. In one report, three five-minute cycles of ischemia to one upper extremity prevented endothelial dysfunction induced by subsequent ischemia to the contralateral upper extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NONISCHEMIC PRECONDITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;While ischemic preconditioning is a well established phenomenon, preconditioning may also be induced by an increase in oxygen demand as, for example, during tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/97\">",
"     97",
"    </a>",
"    ]. In an animal study, tachycardia in the absence of ischemia decreased infarct size after prolonged coronary artery occlusion followed by release [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9673/abstract/98\">",
"     98",
"    </a>",
"    ]. The protective effect, however, was smaller compared with that resulting from ischemia and appeared to be mediated by adenosine and not by changes in protein kinase C activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ISCHEMIC POSTCONDITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another mechanism for protecting the myocardium is ischemic postconditioning in which a series of brief coronary artery occlusions after a severe ischemic insult protects against ischemic-reperfusion injury. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=see_link&amp;anchor=H26#H26\">",
"     \"Ischemic reperfusion injury of the heart\", section on 'Ischemic postconditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183985101\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic conditioning describes an endogenous phenomenon, in which one or more brief episodes of nonlethal ischemia and reperfusion confer protection against a sustained lethal episode of ischemia and reperfusion. The conditioning stimulus can be applied before (ischemic preconditioning) or after the onset of (ischemic postconditioning) ischemia, or at the transition from sustained ischemia to reperfusion (ischemic postconditioning). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ischemic preconditioning'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Ischemic postconditioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The conditioning stimulus can be applied either directly to the heart or to a distant organ or tissue, such as a limb (remote ischemic conditioning). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Remote ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elucidation of the mechanistic pathways underlying ischemic conditioning has identified potential pharmacological cardioprotective strategies (pharmacological conditioning), which have been largely unsuccessful in the clinical setting. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mediators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proof-of-concept studies reported benefits with ischemic preconditioning, postconditioning, and remote ischemic conditioning in patients with acute myocardial infarction, and those undergoing cardiac surgery or percutaneous coronary intervention. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ischemic preconditioning'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Remote ischemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Ischemic postconditioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large clinical trials are required to determine whether ischemic conditioning can improve clinical outcomes in patients with coronary heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/1\">",
"      Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/2\">",
"      Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991; 84:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/3\">",
"      Li Y, Kloner RA. The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts. Circulation 1993; 87:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/4\">",
"      Sumeray MS, Yellon DM. Characterisation and validation of a murine model of global ischaemia-reperfusion injury. Mol Cell Biochem 1998; 186:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/5\">",
"      Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990; 66:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/6\">",
"      Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994; 24:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/7\">",
"      Cave AC, Hearse DJ. Ischaemic preconditioning and contractile function: studies with normothermic and hypothermic global ischaemia. J Mol Cell Cardiol 1992; 24:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/8\">",
"      Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol 1987; 253:H1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/9\">",
"      Vegh A, Komori S, Szekeres L, Parratt JR. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 1992; 26:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/10\">",
"      Piot CA, Padmanaban D, Ursell PC, et al. Ischemic preconditioning decreases apoptosis in rat hearts in vivo. Circulation 1997; 96:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/11\">",
"      Schulz R, Post H, Vahlhaus C, Heusch G. Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 1998; 98:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/12\">",
"      Li YW, Whittaker P, Kloner RA. The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. Am Heart J 1992; 123:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/13\">",
"      Murry CE, Richard VJ, Jennings RB, Reimer KA. Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol 1991; 260:H796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/14\">",
"      Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993; 88:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/15\">",
"      Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993; 72:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/16\">",
"      Baxter GF, Goma FM, Yellon DM. Characterisation of the infarct-limiting effect of delayed preconditioning: timecourse and dose-dependency studies in rabbit myocardium. Basic Res Cardiol 1997; 92:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/17\">",
"      Yellon DM, Baxter GF. A \"second window of protection\" or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol 1995; 27:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/18\">",
"      Speechly-Dick ME, Baxter GF, Yellon DM. Ischaemic preconditioning protects hypertrophied myocardium. Cardiovasc Res 1994; 28:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/19\">",
"      Pantos CI, Davos CH, Carageorgiou HC, et al. Ischaemic preconditioning protects against myocardial dysfunction caused by ischaemia in isolated hypertrophied rat hearts. Basic Res Cardiol 1996; 91:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/20\">",
"      Burns PG, Krunkenkamp IB, Calderone CA, et al. Is the preconditioning response conserved in senescent myocardium? Ann Thorac Surg 1996; 61:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/21\">",
"      Abete P, Ferrara N, Cioppa A, et al. Preconditioning does not prevent postischemic dysfunction in aging heart. J Am Coll Cardiol 1996; 27:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/22\">",
"      Tani M, Suganuma Y, Hasegawa H, et al. Changes in ischemic tolerance and effects of ischemic preconditioning in middle-aged rat hearts. Circulation 1997; 95:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/23\">",
"      Miura, T, Adachi, T, Ogawa, T, et al. Myocardial infarct size-limiting effect of ischemic preconditioning: Its natural decay and the effect of repetitive preconditioning. Cardiovasc Pathol 1992; 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/24\">",
"      Yamasaki K, Fujiwara H, Tanaka M, et al. Preconditioning with 15-minute ischemia extends myocardial infarct size after subsequent 30-minute ischemia in rabbits. Jpn Circ J 1997; 61:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/25\">",
"      Figueras J, Segura R, Bermejo B. Repeated 15-minute coronary occlusions in pigs increase occlusion arrhythmias but decrease reperfusion arrhythmias that are associated with extracellular hypokalemia. J Am Coll Cardiol 1996; 28:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/26\">",
"      Li Y, Kloner RA. Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids. Cardiovasc Res 1992; 26:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/27\">",
"      Asimakis GK, Inners-McBride K, Medellin G, Conti VR. Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart. Am J Physiol 1992; 263:H887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/28\">",
"      Matsuda M, Catena TG, Vander Heide RS, et al. Cardiac protection by ischaemic preconditioning is not mediated by myocardial stunning. Cardiovasc Res 1993; 27:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/29\">",
"      de Albuquerque CP, Gerstenblith G, Weiss RG. Importance of metabolic inhibition and cellular pH in mediating preconditioning contractile and metabolic effects in rat hearts. Circ Res 1994; 74:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/30\">",
"      Soares PR, de Albuquerque CP, Chacko VP, et al. Role of preischemic glycogen depletion in the improvement of postischemic metabolic and contractile recovery of ischemia-preconditioned rat hearts. Circulation 1997; 96:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/31\">",
"      Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 2001; 104:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/32\">",
"      Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 2001; 104:3158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/33\">",
"      Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol 1993; 264:H2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/34\">",
"      Banerjee A, Locke-Winter C, Rogers KB, et al. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res 1993; 73:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/35\">",
"      Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995; 27:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/36\">",
"      Goto M, Liu Y, Yang XM, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995; 77:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/37\">",
"      Erikson JM, Velasco CE. Endothelin-1 and myocardial preconditioning. Am Heart J 1996; 132:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/38\">",
"      Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996; 78:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/39\">",
"      Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 1997; 29:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/40\">",
"      Morris SD, Yellon DM. Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol 1997; 29:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/41\">",
"      Mullane K, Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J Mol Cell Cardiol 1995; 27:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/42\">",
"      Vogt AM, Ando H, Arras M, Els&auml;sser A. Lack of adenosine causes myocardial refractoriness. J Am Coll Cardiol 1998; 31:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/43\">",
"      Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998; 31:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/44\">",
"      Downey JM, Cohen MV. Signal transduction in ischemic preconditioning. Z Kardiol 1995; 84 Suppl 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/45\">",
"      Node K, Kitakaze M, Sato H, et al. Role of intracellular Ca2+ in activation of protein kinase C during ischemic preconditioning. Circulation 1997; 96:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/46\">",
"      Przyklenk K, Hata K, Kloner RA. Is calcium a mediator of infarct size reduction with preconditioning in canine myocardium? Circulation 1997; 96:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/47\">",
"      Kitakaze M, Node K, Minamino T, et al. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. Circulation 1996; 93:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/48\">",
"      Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994; 266:H1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/49\">",
"      Nakano A, Baines CP, Kim SO, et al. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: evidence for involvement of p38 MAPK. Circ Res 2000; 86:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/50\">",
"      Sanada S, Asanuma H, Tsukamoto O, et al. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004; 110:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/51\">",
"      Baines CP, Wang L, Cohen MV, Downey JM. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J Mol Cell Cardiol 1998; 30:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/52\">",
"      Gross GJ, Mei DA, Schultz JJ, Mizumura T. Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? Basic Res Cardiol 1996; 91:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/53\">",
"      Sato T, Sasaki N, Seharaseyon J, et al. Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection. Circulation 2000; 101:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/54\">",
"      Minners J, van den Bos EJ, Yellon DM, et al. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc Res 2000; 47:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/55\">",
"      Schulz R, Rose J, Heusch G. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine. Am J Physiol 1994; 267:H1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/56\">",
"      Miura T, Kawamura S, Tatsuno H, et al. Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation 2001; 104:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/57\">",
"      Jovanovi�� A, Jovanovi�� S, Lorenz E, Terzic A. Recombinant cardiac ATP-sensitive K+ channel subunits confer resistance to chemical hypoxia-reoxygenation injury. Circulation 1998; 98:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/58\">",
"      Ghosh S, Standen NB, Gali&ntilde;ianes M. Failure to precondition pathological human myocardium. J Am Coll Cardiol 2001; 37:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/59\">",
"      Hu K, Duan D, Li GR, Nattel S. Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Circ Res 1996; 78:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/60\">",
"      Liu Y, Gao WD, O'Rourke B, Marban E. Synergistic modulation of ATP-sensitive K+ currents by protein kinase C and adenosine. Implications for ischemic preconditioning. Circ Res 1996; 78:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/61\">",
"      Sato T, Sasaki N, O'Rourke B, Marb&aacute;n E. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: a key step in ischemic preconditioning? Circulation 2000; 102:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/62\">",
"      Bell SP, Sack MN, Patel A, et al. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 2000; 36:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/63\">",
"      Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995; 268:H2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/64\">",
"      Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart. J Mol Cell Cardiol 1997; 29:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/65\">",
"      McPherson BC, Yao Z. Morphine mimics preconditioning via free radical signals and mitochondrial K(ATP) channels in myocytes. Circulation 2001; 103:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/66\">",
"      Liang BT, Gross GJ. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels. Circ Res 1999; 84:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/67\">",
"      Vanden Hoek TL, Becker LB, Shao Z, et al. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem 1998; 273:18092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/68\">",
"      Samavati L, Monick MM, Sanlioglu S, et al. Mitochondrial K(ATP) channel openers activate the ERK kinase by an oxidant-dependent mechanism. Am J Physiol Cell Physiol 2002; 283:C273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/69\">",
"      Yue Y, Krenz M, Cohen MV, et al. Menadione mimics the infarct-limiting effect of preconditioning in isolated rat hearts. Am J Physiol Heart Circ Physiol 2001; 281:H590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/70\">",
"      Tritto I, D'Andrea D, Eramo N, et al. Oxygen radicals can induce preconditioning in rabbit hearts. Circ Res 1997; 80:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/71\">",
"      Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res 2001; 88:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/72\">",
"      Crestanello JA, Lingle DM, Kamelgard J, et al. Ischemic preconditioning decreases oxidative stress during reperfusion: a chemiluminescence study. J Surg Res 1996; 65:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/73\">",
"      Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 2000; 87:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/74\">",
"      Krieg T, Cui L, Qin Q, et al. Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF. J Mol Cell Cardiol 2004; 36:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/75\">",
"      Krieg T, Qin Q, Philipp S, et al. Acetylcholine and bradykinin trigger preconditioning in the heart through a pathway that includes Akt and NOS. Am J Physiol Heart Circ Physiol 2004; 287:H2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/76\">",
"      Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005; 288:H971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/77\">",
"      Strohm C, Barancik T, Br&uuml;hl ML, et al. Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J Cardiovasc Pharmacol 2000; 36:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/78\">",
"      Oldenburg O, Qin Q, Krieg T, et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol 2004; 286:H468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/79\">",
"      Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/80\">",
"      Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/81\">",
"      Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995; 307 ( Pt 1):93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/82\">",
"      Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341 ( Pt 2):233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/83\">",
"      Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation 1997; 96:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/84\">",
"      Baxter GF, Marber MS, Patel VC, Yellon DM. Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning. Circulation 1994; 90:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/85\">",
"      Dana A, Jonassen AK, Yamashita N, Yellon DM. Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase. Circulation 2000; 101:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/86\">",
"      Takano H, Manchikalapudi S, Tang XL, et al. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 1998; 98:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/87\">",
"      Guo Y, Jones WK, Xuan YT, et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 1999; 96:11507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/88\">",
"      Sun JZ, Tang XL, Park SW, et al. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest 1996; 97:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/89\">",
"      Bolli R, Bhatti ZA, Tang XL, et al. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ Res 1997; 81:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/90\">",
"      Sasaki N, Sato T, Ohler A, et al. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/91\">",
"      Vegh A, Papp JG, Parratt JR. Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing. Br J Pharmacol 1994; 113:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/92\">",
"      Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002; 55:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/93\">",
"      Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000; 97:10197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/94\">",
"      Shinmura K, Xuan YT, Tang XL, et al. Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 2002; 90:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/95\">",
"      Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997; 96:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/96\">",
"      Kharbanda RK, Mortensen UM, White PA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002; 106:2881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/97\">",
"      Koning MM, Gho BC, van Klaarwater E, et al. Rapid ventricular pacing produces myocardial protection by nonischemic activation of KATP+ channels. Circulation 1996; 93:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9673/abstract/98\">",
"      Domenech RJ, Macho P, V&eacute;lez D, et al. Tachycardia preconditions infarct size in dogs: role of adenosine and protein kinase C. Circulation 1998; 97:786.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1487 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-4B4EEE0DB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9673=[""].join("\n");
var outline_f9_28_9673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H183985101\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISCHEMIC PRECONDITIONING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Duration of ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mediators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Timing of activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adenosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Protein kinase C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ATP-dependent potassium channels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Opioid receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Reactive oxygen species",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Prosurvival kinases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Inhibition of MPTP opening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Second window of protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      REMOTE ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NONISCHEMIC PRECONDITIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ISCHEMIC POSTCONDITIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H183985101\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1487\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1487|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/5/11347\" title=\"algorithm 1\">",
"      Ischemic preconditioning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=related_link\">",
"      Coronary collateral circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=related_link\">",
"      Ischemic reperfusion injury of the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_28_9674="Clinical spectrum of antineutrophil cytoplasmic antibodies";
var content_f9_28_9674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical spectrum of antineutrophil cytoplasmic antibodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9674/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9674/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9674/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9674/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9674/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/28/9674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/28/9674/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/28/9674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1982, antibodies directed against neutrophil cytoplasmic antigens were first described in patients with pauci-immune glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/1\">",
"     1",
"    </a>",
"    ]. These antibodies were initially believed to be associated with Ross River virus infections. By 1985, however, antineutrophil cytoplasmic antibodies (ANCA) had been linked to granulomatosis with polyangiitis (Wegener's), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/2\">",
"     2",
"    </a>",
"    ]. Within several more years, a relationship among ANCA, GPA, microscopic polyangiitis (MPA), and \"renal-limited\" vasculitis (pauci-immune glomerulonephritis without evidence of extrarenal disease) had been established [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. ANCA testing currently plays a critical role in the diagnosis and classification of vasculitides, even as debate about their ultimate importance in the pathogenesis and pathophysiology of these conditions continues.",
"   </p>",
"   <p>",
"    Following a brief discussion of certain technical issues related to the performance of ANCA assays, a review of the disease associations of ANCA and clinical utility of ANCA testing will be presented here. The role of ANCA in the pathogenesis of GPA and related vasculitides is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of ANCA assays are currently in wide use:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Indirect immunofluorescence assay, using alcohol fixed buffy coat leukocytes",
"     </li>",
"     <li>",
"      Enzyme-linked immunosorbent assay (ELISA), using purified specific antigens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these two techniques, the immunofluorescence assay is more sensitive and the ELISA more specific. The optimal approach to clinical testing for ANCA is therefore to screen with immunofluorescence assays, if available, and to confirm all positive results with ELISAs directed against the vasculitis-specific target antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, since ANCA testing is not standardized, the sensitivity and specificity will vary with the laboratory; there are also no reference values for normal. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Caution when interpreting positive immunofluorescence results'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In vasculitis, the two relevant target antigens are proteinase 3 (PR3) and myeloperoxidase (MPO). Both PR3 and MPO are located in the azurophilic granules of neutrophils and the peroxidase-positive lysosomes of monocytes. Antibodies with target specificities for PR3 and MPO are called PR3-ANCA and MPO-ANCA, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunofluorescence patterns in vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the sera of patients with ANCA-associated vasculitis are incubated with ethanol-fixed human neutrophils, two major immunofluorescence patterns are observed (",
"    <a class=\"graphic graphic_picture graphicRef66748 graphicRef78968 \" href=\"UTD.htm?26/1/26640\">",
"     picture 1A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the C-ANCA pattern, the staining is diffuse throughout the cytoplasm. In most cases, antibodies directed against PR3 cause this pattern [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/7,8\">",
"       7,8",
"      </a>",
"      ], but MPO-ANCA can occasionally be responsible.",
"     </li>",
"     <li>",
"      The perinuclear or P-ANCA pattern results from a staining pattern around the nucleus, which represents an artifact of ethanol fixation. With ethanol fixation of the neutrophil substrate, positively-charged granule constituents rearrange themselves around the negatively-charged nuclear membrane, leading to perinuclear fluorescence [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/3\">",
"       3",
"      </a>",
"      ]. Among vasculitis patients, the antibody responsible for this pattern is usually directed against MPO (and only occasionally PR3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunofluorescence patterns in non-vasculitic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical ANCA patterns may be observed on immunofluorescence testing in patients with immune-mediated conditions other than systemic vasculitis (eg, connective tissue disorders, inflammatory bowel disease, and autoimmune hepatitis). Such patterns may be confused with P-ANCA patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Caution when interpreting positive immunofluorescence results",
"    </span>",
"    &nbsp;&mdash;&nbsp;For several reasons, caution is required in the interpretation of both positive C- and P-ANCA immunofluorescence patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a subjective component to the interpretation of immunofluorescence assays, because the tests are based upon visual interpretation of the IF pattern; this is sometimes not straightforward. Thus, the positive or negative predictive value of a given test result depends upon the experience of the individual who performs the assay. The positive and negative predictive values are likely to be better with results from a research laboratory than with a commercial assay.",
"     </li>",
"     <li>",
"      ANCA testing remains unstandardized and there are no references for normal ranges. In sizing up the utility of ANCA testing in clinical practice, it must be borne in mind that most studies of ANCA serologies have been performed at tertiary care centers using research laboratories focused on ANCA testing. Translating the test characteristics from the environments of research laboratories to clinical practice must be done with caution.",
"     </li>",
"     <li>",
"      Immunofluorescence results are not highly specific. The C-ANCA pattern has a greater specificity than the P-ANCA pattern for vasculitis (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Disease associations'",
"      </a>",
"      below). However, in one series of consecutive assays from a tertiary care center, even positive C-ANCA immunofluorescence results were associated with vasculitis in only 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/9\">",
"       9",
"      </a>",
"      ]. In another study, the positive predictive value for granulomatosis with polyangiitis (Wegener's) of a C-ANCA pattern was only 28 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to a host of azurophilic granule proteins can cause a P-ANCA staining pattern. These include antibodies directed against lactoferrin, elastase, cathepsin G, bactericidal permeability inhibitor, catalase, lysozyme, beta-glucuronidase, and others. A positive P-ANCA immunofluorescence staining pattern may also be detected in a wide variety of inflammatory illnesses, and has a low specificity for vasculitis. A positive immunofluorescence assay should therefore always prompt testing by ELISA to determine the specific antibody (or antibodies) responsible for the pattern.",
"     </li>",
"     <li>",
"      Because of the frequent difficulty in distinguishing the P-ANCA pattern of immunofluorescence from that caused by antinuclear antibodies (ANA), individuals with ANA frequently have \"false-positive\" results on ANCA testing by immunofluorescence. Rigorous immunofluorescence testing procedures for ANCA include the use of both formalin- and ethanol-fixed neutrophil substrates; this is because formalin-fixed neutrophils prevent the rearrangement of charged cellular components around the nucleus. The use of both cell substrates permits the distinction between antibodies causing a \"true\" P-ANCA pattern and those directed against the nuclear antigens (ANA). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"       \"Measurement and clinical significance of antinuclear antibodies\"",
"      </a>",
"      .) Immunofluorescence assays on both formalin and ethanol-fixed substrates should be routinely done on all ANCA assays.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Enzyme-linked immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific ELISAs for antibodies to PR3 and MPO are commercially available, and should be part of any standardized approach to the testing for ANCA. PR3-ANCA and MPO-ANCA are associated with substantially higher specificities and positive predictive values than the immunofluorescence patterns to which they usually correspond (C- and P-ANCA, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/11\">",
"     11",
"    </a>",
"    ]. However, errors can be made if these tests are not performed in experienced laboratories. ELISAs for other antigens are also available, but the indications for their use are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA are associated with many cases of granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, MPA, the Churg-Strauss syndrome (CSS), \"renal-limited\" vasculitis, and certain drug-induced vasculitis syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/12\">",
"     12",
"    </a>",
"    ]. In these conditions, ANCA consistently have specificities for either PR3 or MPO, but almost never for both.",
"   </p>",
"   <p>",
"    In contrast to these conditions, classic polyarteritis nodosa is not associated with PR3- or MPO-ANCA and the presence of one of these antibodies suggests an alternative diagnosis. ANCA that have different antigen specificities may be detected in a variety of gastrointestinal and other rheumatic disorders, particularly by immunofluorescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Granulomatosis with polyangiitis (Wegener's)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately",
"    <strong>",
"     90 percent",
"    </strong>",
"    of patients with active, generalized granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, are ANCA-positive. There is clearly a small subset of patients with active, generalized GPA who do not have ANCA. Furthermore, in limited forms of the disease (such as subsets in which upper respiratory tract disease predominates and renal involvement is absent), up to 40 percent of patients may be ANCA-negative. Thus, the absence of ANCA",
"    <strong>",
"     does not",
"    </strong>",
"    exclude the diagnosis of GPA. In large measure, the sensitivity of PR3-ANCA for GPA is related to the extent, severity, and activity of disease at the time of sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among GPA patients with ANCA, 80 to 90 percent, have PR3-ANCA. The remainder of ANCA-positive GPA patients have MPO-ANCA. Necrotizing granulomatous inflammation, the histopathologic hallmark of GPA, has been reported in both PR3- and MPO-ANCA positive individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Microscopic polyangiitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of patients with microscopic polyangiitis (MPA) are ANCA positive [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast to GPA, most ANCA-positive MPA patients have MPO-ANCA, with a minority having PR3-ANCA. Because PR3-ANCA or MPO-ANCA may occur in both GPA and MPA, these diseases cannot be distinguished on the basis of ANCA specificity. Data pertaining to ANCA and MPA are also complicated by the lack of consensus concerning the definition of MPA. The distinction between GPA and MPA is important chiefly because of differential tendencies to flare. Although both diseases may flare after the achievement of remission, GPA is substantially more likely to relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H4#H4\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ANCA serologies are useful in distinguishing MPA from classic polyarteritis nodosa (PAN), a vasculitis of medium-sized muscular arteries. Whereas nearly three-fourths of patients with MPA are ANCA-positive, classic PAN is",
"    <strong>",
"     not",
"    </strong>",
"    associated with antibodies to either PR3 or MPO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal-limited vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pauci-immune vasculitis limited to the kidney is characterized by necrotizing glomerulonephritis with little or no deposition of immunoreactants (IgG, IgM, IgA, and complement components). The majority of patients with renal-limited vasculitis are ANCA-positive, with 75 to 80 percent having MPO-ANCA. More limited data suggest that antibodies directed against another ANCA subtype, lysosome associated membrane protein-2 (LAMP-2), are pathogenetically important in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\", section on 'Anti-LAMP-2 antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ANCA-positive pauci-immune necrotizing glomerulonephritis is considered to be part of the",
"    <span class=\"nowrap\">",
"     GPA/MPA",
"    </span>",
"    spectrum because the histopathologic findings in the kidney are indistinguishable from those of the glomerulonephritis in GPA or MPA and because some patients who present with disease limited to the kidney eventually exhibit extrarenal manifestations of either GPA or MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H121321784#H121321784\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Renal-limited vasculitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Churg-Strauss syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA, both PR3 and MPO, have been detected with variable frequencies in patients with Churg-Strauss syndrome (CSS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. Approximately 50 percent of CSS patients overall are ANCA positive, with the percentage being somewhat higher in those with active, untreated disease. There appears to be a moderate predilection for MPO-ANCA among those patients with CSS who have ANCA. As an example, in one series, 40 of 102 patients with CSS were ANCA positive, and 29 (73 percent) had specificity for MPO-ANCA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest the possibility of phenotypic differences among patients with CSS who are ANCA positive as opposed to ANCA negative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. ANCA positive patients are more likely to have glomerulonephritis, alveolar hemorrhage, and neurologic disease, whereas ANCA-negative patients are more likely to have cardiac and other pulmonary involvement. However, the state of the literature is far from a consensus on this point. There is certainly overlap in clinical phenotypes among patients with and without ANCA (as is true in GPA and MPA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Anti-GBM antibody disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 10 and 40 percent of patients with anti-glomerular basement membrane (GBM) antibody disease are ANCA-positive at the time of diagnosis, and ANCA is usually directed against MPO rather than PR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that 38 of 100 sera with anti-GBM antibodies also had ANCA [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/26\">",
"       26",
"      </a>",
"      ]; 25 had MPO-ANCA, 12 had PR3-ANCA, and 1 had both.",
"     </li>",
"     <li>",
"      Another reported that 27 of 121 sera confirmed to be positive for anti-GBM after initial testing also had detectable ANCA [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/28\">",
"       28",
"      </a>",
"      ]. MPO-ANCA, PR3-ANCA, or both were detected in 22, 1, and 4 sera, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with both ANCA and anti-GBM antibodies, the relationship between the two antibodies is unknown. The antigen specificity for the anti-GBM antibodies is the same as in patients with anti-GBM antibody disease alone, suggesting that the inciting antigen is the same [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the production of ANCA appears to precede that of anti-GBM antibodies at least in some patients. This was demonstrated in an analysis of stored serum samples that had been obtained at the time of enlistment and every other year thereafter from 30 US military personnel who subsequently developed anti-GBM disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients who were diagnosed with anti-GBM disease and healthy controls were identified from the military database and serum samples obtained from the Department of Defense Stored Serum Repository. Compared with matching controls, a greater number of patients with anti-GBM disease had PR3-ANCA and MPO-ANCA levels detected in multiple serum samples that had been obtained in the years preceding the onset of disease (82 versus 14 percent in controls for PR3-ANCA, and 73 versus 27 percent in controls for MPO-ANCA). In all cases, ANCA antibodies were detected in earlier samples than anti-GBM antibodies, which were detected months, but not years, prior to the onset of clinical symptoms. These data suggest the possibility that the pulmonary or renal damage caused by ANCA may lead to secondary anti-GBM antibody formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"     \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical significance of combined ANCA and anti-GBM antibodies is unclear. In some patients with both antibodies, there are no clinical manifestations of GPA MPA, or CSS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Others present with disease features that are uncommon to anti-GBM antibody disease but quite typical of systemic vasculitis (purpura, arthralgias, and granulomatous inflammation), suggesting the concurrence of two disease processes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/25\">",
"     25",
"    </a>",
"    ]. In some studies, the presence of both antibodies was associated with a worse renal prognosis than is the presence of either antibody alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. In a retrospective study of kidney biopsies with crescentic GN, the histology of double positive patients (MPO-ANCA and anti-GBM) was indistinguishable from the histology with MPO-ANCA alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features at presentation of patients with such double-positive sera were perhaps best described in a retrospective study of all serologic assays performed at a single tertiary care hospital in England between 1990 and 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/28\">",
"     28",
"    </a>",
"    ]. Among 27 patients with true double-positive sera (ANCA plus anti-GBM antibodies that were identical to those with isolated anti-GBM antibodies), the following presenting clinical features were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal disease (100 percent), with a median serum creatinine concentration of 7.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (636",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      Seventy percent required dialysis within 48 hours of presentation.",
"     </li>",
"     <li>",
"      Malaise and general weakness (44 percent)",
"     </li>",
"     <li>",
"      Pulmonary hemorrhage (41 percent)",
"     </li>",
"     <li>",
"      Rash (22 percent)",
"     </li>",
"     <li>",
"      Other respiratory symptoms (19 percent)",
"     </li>",
"     <li>",
"      Ear, nose, and throat or sinus symptoms (11 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19762502\">",
"    <span class=\"h2\">",
"     Other concurrent glomerular diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to anti-GBM antibody disease, ANCA-associated glomerular disease has also been described in a variety of other glomerular diseases including membranous nephropathy, lupus nephritis, IgA nephropathy, and bacterial infection-related glomerulonephritis (mostly poststreptococcal and Staphylococcus-associated). This issue is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H934547#H934547\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Concurrent glomerular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Drug-induced ANCA-associated vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain medications may induce forms of vasculitis associated with ANCA. Most patients reported with drug-induced ANCA associated vasculitis have MPO-ANCA, frequently in very high titers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition to MPO-ANCA, most also have antibodies to elastase or to lactoferrin. A small number have PR3-ANCA. In one study of 209 patients with hyperthyroidism, 13 (6 percent) were positive for either MPO- or PR3-ANCA or for ANCA directed against human leukocyte elastase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/33\">",
"     33",
"    </a>",
"    ]. The presence of ANCA was highly associated with treatment with antithyroid drugs (odds ratio 11.8, 95% CI of 1.5 to 93.3). ANCA positivity with glomerulonephritis developed in approximately one-third (4 of 13). The presence of ANCA with or without vasculitis is associated with previous treatment with antithyroid drugs, possibly after many years of exposure. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Propylthiouracil'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many cases of drug-induced ANCA-associated vasculitis are associated with constitutional symptoms,",
"    <span class=\"nowrap\">",
"     arthralgias/arthritis,",
"    </span>",
"    and cutaneous vasculitis. However, the full range of clinical features associated with ANCA, including crescentic glomerulonephritis and alveolar hemorrhage, can also occur.",
"   </p>",
"   <p>",
"    The strongest links between medications and ANCA-associated vasculitis are with drugs employed in the treatment of hyperthyroidism:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    , and carbimazole.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    are less commonly associated with the induction of ANCA-associated vasculitis (as discussed below, many cases of \"drug-induced lupus\" are actually drug-induced ANCA-associated vasculitis). Other implicated drugs in clinical use include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , thiamazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , rifampicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/34-38\">",
"     34-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug-induced, ANCA-associated vasculitis is sufficiently uncommon that the possibility of this complication should not preclude the use of medications associated with this condition. However, physicians frequently utilizing these medications should be aware of the potential for the development of ANCA-associated vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Propylthiouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTU may be the most common offending agent in drug-induced ANCA seropositivity. In general, patients with this complication have taken the medication for months or even years. A relatively high percentage of patients administered PTU develop ANCA. In a cross-sectional study, for example, 27 percent of patients receiving long-term treatment with PTU developed MPO-ANCA seropositivity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/39\">",
"     39",
"    </a>",
"    ]. However, only a small proportion of such patients develop clinical vasculitis.",
"   </p>",
"   <p>",
"    Although the mechanism of ANCA-seropositivity and vasculitis caused by PTU has not been well defined, it is known that PTU accumulates in neutrophils and that it binds to and alters the MPO antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This alteration could potentially lead to the formation of autoantibodies in susceptible individuals.",
"   </p>",
"   <p>",
"    In patients who develop a vasculitis, the syndrome usually resolves with discontinuation of PTU, but severe cases may require treatment with corticosteroids and other immunosuppression. ANCA titers usually persist in low titers, even after active vasculitis has abated. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hydralazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    has been associated with two drug-induced rheumatic syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug-induced lupus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"       \"Drug-induced lupus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug-induced ANCA-associated vasculitis, which is a potentially more serious condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike the lupus syndrome caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , hydralazine-induced ANCA-associated vasculitis is frequently associated with renal involvement (a pauci-immune glomerulonephritis), antibodies to double-stranded DNA, and high titers of MPO-ANCA; such patients require immunosuppressive therapy in addition to withdrawal of hydralazine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/32,42\">",
"     32,42",
"    </a>",
"    ]. In a report of 10 cases of hydralazine-associated ANCA vasculitis, nine had renal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/32\">",
"     32",
"    </a>",
"    ]. Despite corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (10 and 8 patients, respectively), two patients died, and three required hemodialysis (two of whom eventually recovered). At six month follow-up, seven patients were in remission. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Minocycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    has been associated with arthritis, fever, livedo reticularis, and the induction of ANCA in a report of seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/43\">",
"     43",
"    </a>",
"    ]. The P-ANCA immunofluorescence pattern typically associated with this disorder is usually directed against minor antigens such as cathepsin G, elastase, and bactericidal permeability increasing protein rather than against MPO [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Symptoms typically resolve with the cessation of minocycline therapy, and recur with drug rechallenge. Some patients require treatment with glucocorticoids.",
"   </p>",
"   <p>",
"    More serious manifestations of an ANCA-positive vasculitis have been described in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    therapy, including crescentic glomerulonephritis, a lupus-like syndrome, and cutaneous polyarteritis nodosa [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of drug-associated ANCA vasculitis and the course of the disease are uncertain given the limited reports in the literature. Discontinuation of the offending agent may be the only intervention necessary for mild cases of ANCA-associated vasculitis induced by medications. Examples include cases presenting with constitutional symptoms,",
"    <span class=\"nowrap\">",
"     arthralgias/arthritis,",
"    </span>",
"    or cutaneous vasculitis, but",
"    <strong>",
"     without",
"    </strong>",
"    lung or kidney involvement.",
"   </p>",
"   <p>",
"    Patients with more severe disease manifestations such as lung or kidney involvement, which are common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , require treatment with high doses of corticosteroids and even",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of recurrence with re-exposure to the drug is unclear. Given the potential morbidity associated with drug-induced ANCA vasculitis, we do not recommend rechallenge with the potentially offending agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Drug-induced interstitial nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute drug-induced interstitial nephritis has occasionally been associated with ANCA formation, with the ANCA reacting against MPO, elastase, and lactoferrin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/49\">",
"     49",
"    </a>",
"    ]. Interstitial nephritis may also be seen with ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nonvasculitic rheumatic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA have been reported in virtually all inflammatory rheumatic conditions, including rheumatoid arthritis, systemic lupus erythematosus (SLE), Sj&ouml;gren's syndrome, inflammatory myopathies, juvenile chronic arthritis, reactive arthritis, relapsing polychondritis, scleroderma, and the antiphospholipid syndrome. In most cases, the immunofluorescence pattern is P-ANCA. Atypical fluorescence patterns also occur in these settings, while C-ANCA patterns are rare.",
"   </p>",
"   <p>",
"    The clinical significance of the nonspecific findings in these disorders is unclear. Many reports of ANCA in these diseases preceded the availability of reliable ELISAs for PR3- and MPO-ANCA, and ANCA were detected with only immunofluorescence assays. A multitude of target antigens has been described in patients with these disorders, including lactoferrin, elastase, lysozyme, cathepsin G, and others. In some cases, the specific target antigen remains to be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Autoimmune gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA-positivity is seen in 60 to 80 percent of patients with ulcerative colitis and the related disorder primary sclerosing cholangitis. It is observed in only 10 to 27 percent of patients with Crohn's disease, in whom only low titers are present.",
"   </p>",
"   <p>",
"    The P-ANCA in these conditions appears to be predominantly directed against a myeloid cell-specific 50-kilodalton nuclear envelope protein [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/50\">",
"     50",
"    </a>",
"    ]. Other reported antigen targets include BPI, lactoferrin, cathepsin G, elastase, lysozyme, and PR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenetic significance of these antibodies is unclear. The titers of ANCA do not vary with the activity or severity of the disease and, in ulcerative colitis, do not fall after colectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-MPO P-ANCA are common in patients with cystic fibrosis, particularly among those with bacterial airway infections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The ANCA is directed against BPI",
"    <span class=\"nowrap\">",
"     (bactericidal/permeability-increasing",
"    </span>",
"    protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/52\">",
"     52",
"    </a>",
"    ]. In one series of 66 patients with cystic fibrosis, BPI-IgG and BPI-IgA ANCA were found in 91 and 83 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/52\">",
"     52",
"    </a>",
"    ]. Anti-BPI titers were directly related to the severity of airway destruction. It is unclear whether this relationship represents an epiphenomenon or a response (adaptive or maladaptive) to gram-negative infection with release of endotoxin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265754241\">",
"    <span class=\"h2\">",
"     Cocaine and levamisole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of cocaine bought illicitly in the United States is contaminated or &ldquo;cut&rdquo; with levamisole, an immunomodulatory agent. The use of levamisole-contaminated cocaine is associated with ANCA vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. The largest series, reported from the Massachusetts General Hospital ANCA laboratory, described 30 patients who presented between 2009 and 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/54\">",
"     54",
"    </a>",
"    ]. The most common clinical manifestations included arthralgias (83 percent) and skin lesions (61 percent). Seventy-two percent of patients reported fever, night sweats, weight loss, myalgias or other constitutional symptoms. All patients had a positive MPO-ANCA and 50 percent had positive PR3-ANCA. Twenty-eight percent of patients had leukopenia. An abnormal urinalysis (including either proteinuria, hematuria or cellular casts) was present in eight patients and two patients developed pulmonary hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above disease associations, ANCA has also been observed in isolated patients with autoimmune hepatitis, leprosy, Buerger's disease, malaria, preeclampsia and eclampsia, subacute bacterial endocarditis, diffuse alveolar hemorrhage, chronic graft-versus-host disease, acute parvovirus B19 infection, acute infectious mononucleosis, and cocaine-induced osteochondral destruction (cocaine-induced midline destructive lesions) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/58-64\">",
"     58-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensive use and frequent misuse of ANCA in clinical practice raises a number of critical issues:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is a positive test result a \"true-positive\"?",
"     </li>",
"     <li>",
"      Does a negative ANCA assay exclude an \"ANCA-associated\" vasculitis?",
"     </li>",
"     <li>",
"      Is the presence of a positive ANCA assay in and of itself sufficient to establish the diagnosis (ie, does it preclude the need for biopsy?)",
"     </li>",
"     <li>",
"      Does an increase in ANCA titer predict a disease flare?",
"     </li>",
"     <li>",
"      Does a persistently negative ANCA ensure disease quiescence?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interpretation of the discussion below for clinical practice must take into consideration that the literature upon which it is based reports on test results obtained in research laboratories, which have greater positive and negative predictive values than test results obtained from commercial labs. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Caution when interpreting positive immunofluorescence results'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Is a positive test result a \"true-positive\"?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pitfalls of reliance upon immunofluorescence testing alone are described in detail in previous sections. Both C- and P-ANCA immunofluorescence results should always be",
"    <strong>",
"     confirmed",
"    </strong>",
"    by the performance of antigen-specific ELISAs for PR3- and MPO-ANCA.",
"   </p>",
"   <p>",
"    Using immunofluorescence and ELISA testing in a sequential fashion substantially increases the positive predictive value of an ANCA assay. In one study involving consecutively-tested patients from a tertiary care center, the positive predictive value of ELISA (combined testing for anti-PR3 and anti-MPO antibodies) for ANCA associated vasculitis was superior to that of immunofluorescence (83 versus 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/9\">",
"     9",
"    </a>",
"    ]. For patients with both positive immunofluorescence tests and positive ELISA tests, the positive predictive value increased to 88 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Does a negative ANCA assay exclude a small vessel vasculitis (GPA, MPA, CSS, and renal-limited disease)?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because up to 40 percent of patients with limited granulomatosis with polyangiitis (Wegener's), abbreviated as GPA (and 10 percent of those with severe disease) do not have ANCA, a negative ANCA assay does not exclude GPA. In addition, 30 percent of all MPA patients and perhaps 50 percent of those with CSS are also ANCA-negative. Furthermore, ANCA status may change over time; a patient who is ANCA negative upon presentation with constitutional symptoms and pulmonary infiltrates may become PR3-ANCA positive upon the development of more generalized disease (eg, the occurrence of glomerulonephritis). A negative ANCA assay may therefore create a false sense of security.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Does a positive ANCA obviate the need for confirmation of the diagnosis by tissue biopsy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of ANCA testing depends heavily upon the clinical presentation of the patient in whom the test is performed. As an example, the finding of an elevated ANCA titer in a patient presenting with acute or rapidly progressive glomerulonephritis predicts the presence of GPA, MPA, or idiopathic necrotizing glomerulonephritis with an accuracy that approaches 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/7,65\">",
"     7,65",
"    </a>",
"    ]. However, the diagnostic accuracy of ANCA is substantially lower in patients whose clinical features are less compelling, such as those with only chronic sinusitis as a complaint.",
"   </p>",
"   <p>",
"    The diagnostic accuracy of ANCA was evaluated in a large multicenter European collaborative study. Investigators compared 169 newly diagnosed and 189 previously-diagnosed patients with idiopathic systemic vasculitis or rapidly progressive glomerulonephritis with 184 disease controls (including those with other vasculitides, such as giant cell or Takayasu arteritis, or nonvasculitic glomerulonephritides) and 740 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/6\">",
"     6",
"    </a>",
"    ]. Both indirect immunofluorescence testing and specific anti-PR3 and anti-MPO (ELISAs) were performed. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In GPA, the sensitivity of C-ANCA, P-ANCA, anti-PR3, and anti-MPO, was 64, 21, 66, and 24 percent, respectively. In microscopic polyarteritis, the sensitivities were 23, 58, 26, and 58 percent, respectively. In idiopathic rapidly glomerulonephritis, the sensitivities were 36, 45, 50, and 64 percent, respectively.",
"     </li>",
"     <li>",
"      Compared to the results in disease controls, the specificity of C-ANCA, P-ANCA, anti-PR3, and anti-MPO was 95, 81, 87, and 91 percent, respectively.",
"     </li>",
"     <li>",
"      The combination of indirect immunofluorescence and ELISA testing resulted in increased sensitivity and specificity. The sensitivity of either C-ANCA plus anti-PR3 or P-ANCA plus anti-MPO was 73, 67, and 82 percent for GPA, microscopic polyangiitis, and pauci-immune crescentic glomerulonephritis, respectively. Specificity was",
"      <strong>",
"       99 percent",
"      </strong>",
"      for both combinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issue of whether treatment can be undertaken without tissue biopsy is controversial. Some clinicians undertake treatment without tissue biopsy in selected cases in which the clinical presentation is highly consistent with pauci-immune vasculitis and in which the results of ANCA testing are unequivocal (eg, both C-ANCA and PR3-ANCA positive).",
"   </p>",
"   <p>",
"    However, we believe that all reasonable attempts to confirm clinical suspicions with histopathological proof should be undertaken before committing patients to long-term treatment with potentially toxic medications, particularly since the ability to make the clinical diagnosis will vary widely with the experience of the clinician. If a biopsy cannot be immediately obtained, therapy should not be delayed, but a biopsy should be obtained as soon as possible after initiation of therapy. The initiation of therapy without a confirmatory biopsy may be appropriate in selected rare circumstances, such as the severely ill ventilator-dependent patient without extrapulmonary involvement in whom the performance of a lung biopsy to obtain adequate tissue may result in significant morbidity or mortality. Even in this setting, an attempt should be made to confirm the diagnosis by tissue biopsy once the patient is stable.",
"   </p>",
"   <p>",
"    The importance of performing renal biopsies in many clinical settings is emphasized by the finding of a study that combined the results of the European collaborative study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/6\">",
"     6",
"    </a>",
"    ] with those from nearly 4200 consecutive patients from the University of North Carolina group [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/7\">",
"     7",
"    </a>",
"    ]. The predictive value of serologic testing was assessed based upon a sensitivity and specificity of 72.5 and 98.4 percent, respectively (values similar to those obtained with combined indirect immunofluorescence and ELISA testing). The predictive value of ANCA varied markedly depending upon the degree of renal disease at presentation (",
"    <a class=\"graphic graphic_table graphicRef75605 graphicRef68525 graphicRef56692 \" href=\"UTD.htm?29/23/30077\">",
"     table 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those with positive ANCA serologies (both immunofluorescence and ELISA) and a clinical presentation of rapidly progressive glomerulonephritis, the positive predictive value of finding a pauci-immune crescentic glomerulonephritis on renal biopsy was at least",
"      <strong>",
"       98 percent",
"      </strong>",
"      in all age groups.",
"     </li>",
"     <li>",
"      By comparison, the positive predictive value of a positive ANCA serologies was only 47 percent among adults with hematuria, proteinuria, and a serum creatinine of less than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (133",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"      Thus, more than half of all such patients with positive ANCA serologies do not have a pauci-immune crescentic glomerulonephritis by renal biopsy, and reliance upon ANCA testing alone would have led to an unacceptably high rate of misdiagnosis. Conversely, however, negative ANCA serologies in this setting were associated with a negative predictive value of",
"      <strong>",
"       99 percent",
"      </strong>",
"      (ie, 99 percent of those with negative ANCA serologies did NOT have a pauci-immune glomerulonephritis on renal biopsy). In this setting, therefore, negative ANCA serologies lend considerable confidence to the exclusion of pauci-immune glomerulonephritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, biopsy is still required to document the presence or absence of a pauci-immune crescentic glomerulonephritis in ANCA-positive patients in whom the tissue diagnosis cannot be confirmed less invasively (eg, biopsy of a nasal lesion). As previously mentioned, many assays currently available are not sufficiently accurate and the potential toxicity of present therapies for ANCA-positive diseases is too great to rely upon serology alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Does a rise in ANCA titers predict a disease flare?",
"    </span>",
"    &nbsp;&mdash;&nbsp;This has been a controversial area in the literature almost since ANCA were first identified in the 1980s. However, several rigorous studies have demonstrated that elevations in the titers of ANCA do NOT predict disease flares in a timely manner [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. The largest of these studies was performed on a clinical trial cohort of 180 patients (WGET Research Group, 2005), with serum samples drawn at three-month intervals and ANCA assays performed at the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/66\">",
"     66",
"    </a>",
"    ]. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who were mature-PR3-ANCA positive compared to negative at baseline, there were no differences in the median time to relapse, disease activity score [",
"      <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/70\">",
"       70",
"      </a>",
"      ], or organ involved at relapse. Decreases in PR3-ANCA levels were not associated with a shorter time to remission, and increases were not associated with relapse",
"     </li>",
"     <li>",
"      Relapses occurred among 46 of 101 patients (46 percent) who were mature-PR3-ANCA positive at baseline and achieved remissions of at least six months' duration. However, the proportion of patients who experienced a disease flare within one year of an elevation in ANCA titer was only 40 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have come to slightly different conclusions, indicating that persistently high or rising titers of ANCA are associated with an increased risk of disease relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. However, even in those studies, the temporal relationship between a rise in ANCA titer and the occurrence of a disease flare was poor. As an example, in a prospective study of 100 ANCA-positive patients observed over a two year period, relapse did not occur in 43 and 29 percent of those with a rise in ANCA titers by immunofluorescence and in PR3-ANCA titers by ELISA, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapies for ANCA-associated vasculitis &mdash; aggressive courses of corticosteroids and cytotoxic agents &mdash; carry substantial risk, including severe infections, cystitis, bladder cancer, lung fibrosis (rarely), and death. Treating all patients with increases in ANCA titers would result in unnecessary risks of toxicity in a substantial percentage of patients, nearly 30 percent in the study mentioned above.",
"   </p>",
"   <p>",
"    Because of these concerns, the use of an elevation in ANCA titer as the",
"    <strong>",
"     sole",
"    </strong>",
"    parameter to justify immunosuppressive therapy",
"    <strong>",
"     cannot",
"    </strong>",
"    be endorsed. A reasonable recommendation is to closely follow patients with rising ANCA titers but not to alter their therapy unless there are clearcut clinical signs of active disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of 22 studies with ANCA-associated vasculitis was unable to conclude that following serial ANCA titers has clinical utility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/73\">",
"     73",
"    </a>",
"    ]. However, a substantial proportion of patients relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/71\">",
"     71",
"    </a>",
"    ]. Therapy should only be instituted if there is unequivocal evidence of clinical relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H8#H8\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'ANCA titers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Does a persistently negative ANCA assure disease quiescence?",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient was ANCA-positive during a period of active disease, a persistently ANCA-negative status is consistent with, but not absolutely proof of, remission. This was illustrated in a report in which 37 of 100 patients with ANCA associated vasculitis suffered flares during the period of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/28/9674/abstract/71\">",
"     71",
"    </a>",
"    ]. Of these, 13 (8 percent) were ANCA negative at the time of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Technical issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA testing currently plays a critical role in the diagnosis and classification of vasculitides. Two types of ANCA assays are currently in wide use:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Indirect immunofluorescence assay",
"     </li>",
"     <li>",
"      Enzyme-linked immunosorbent assay (ELISA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these two techniques, the immunofluorescence assay is more sensitive and the ELISA more specific. The optimal approach to clinical testing for ANCA is therefore to screen with immunofluorescence assays, if available, and to confirm all positive results with ELISAs directed against the vasculitis-specific target antigens.",
"   </p>",
"   <p>",
"    Two major immunofluorescence patterns are observed, the C-ANCA and P-ANCA patterns (",
"    <a class=\"graphic graphic_picture graphicRef66748 graphicRef78968 \" href=\"UTD.htm?26/1/26640\">",
"     picture 1A-B",
"    </a>",
"    ). For several reasons, caution is required in the interpretation of both positive C- and P-ANCA immunofluorescence patterns. These include: the interpretation of immunofluorescence assays is subjective; immunofluorescence results are not highly specific; antibodies to a host of azurophilic granule proteins can cause a P-ANCA staining pattern; and individuals with ANA frequently have \"false-positive\" results on ANCA testing by immunofluorescence.",
"   </p>",
"   <p>",
"    In vasculitis, the two relevant target antigens for ANCA are proteinase 3 (PR3) and myeloperoxidase (MPO). Antibodies with target specificities for PR3 and MPO are called PR3-ANCA and MPO-ANCA, respectively. Specific ELISAs for antibodies to PR3 and MPO are commercially available, and should be part of any standardized approach to the testing for ANCA. PR3-ANCA and MPO-ANCA are associated with substantially higher specificities and positive predictive values than the immunofluorescence patterns to which they usually correspond (C- and P-ANCA, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCA are associated with many cases of granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, MPA, the Churg-Strauss syndrome (CSS), \"renal-limited\" vasculitis, and certain drug-induced vasculitis syndromes. In these conditions, ANCA consistently have specificities for either PR3 or MPO, but almost never for both.",
"   </p>",
"   <p>",
"    ANCA that have different antigen specificities may also be detected in a variety of gastrointestinal and other rheumatic disorders, particularly by immunofluorescence. The clinical significance of the nonspecific findings in these disorders is unclear.",
"   </p>",
"   <p>",
"    Between 10 and 40 percent of patients with anti-glomerular basement membrane (GBM) antibody disease are also ANCA-positive at the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Clinical applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensive use and frequent misuse of ANCA in clinical practice raises a number of critical issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both C- and P-ANCA immunofluorescence results should be",
"      <strong>",
"       confirmed",
"      </strong>",
"      by the performance of antigen-specific ELISAs for PR3- and MPO-ANCA.",
"     </li>",
"     <li>",
"      Because up to 40 percent of patients with limited GPA (and 10 percent of those with severe disease) do not have ANCA, a negative ANCA assay does not exclude GPA. In addition, 30 percent of all MPA patients and perhaps 50 percent of those with CSS are also ANCA-negative. Thus, if the clinical scenario is suggestive, a tissue biopsy should be obtained.",
"     </li>",
"     <li>",
"      When evaluating a patient with a possible \"pulmonary-renal syndrome\", we suggest obtaining both ANCA and anti-GBM assays. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anti-GBM antibody disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predictive value of ANCA testing depends heavily upon the clinical presentation of the patient in whom the test is performed, and the laboratory performing the test. We believe that",
"      <strong>",
"       all",
"      </strong>",
"      reasonable attempts to confirm clinical suspicions with histopathological proof should be undertaken before committing patients to long-term treatment with potentially toxic medications.",
"     </li>",
"     <li>",
"      The use of a rising ANCA titer as the sole parameter to diagnose a relapse and thus justify immunosuppressive therapy",
"      <strong>",
"       cannot",
"      </strong>",
"      be endorsed.",
"     </li>",
"     <li>",
"      If a patient was ANCA-positive during a period of active disease, a persistently ANCA-negative status is consistent with, but not absolutely proof of, remission.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/1\">",
"      Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/2\">",
"      van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/3\">",
"      Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/4\">",
"      Tervaert JW, Goldschmeding R, Elema JD, et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990; 37:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/5\">",
"      Hagen EC, Andrassy K, Csernok E, et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996; 196:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/6\">",
"      Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/7\">",
"      Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int 1998; 53:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/8\">",
"      Niles JL, Pan GL, Collins AB, et al. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. J Am Soc Nephrol 1991; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/9\">",
"      Stone JH, Talor M, Stebbing J, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000; 13:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/10\">",
"      Rao JK, Allen NB, Feussner JR, Weinberger M. A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis. Lancet 1995; 346:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/11\">",
"      Csernok E, Holle J, Hellmich B, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) 2004; 43:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/12\">",
"      Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004; 117:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/13\">",
"      Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/14\">",
"      Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/15\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/16\">",
"      Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/17\">",
"      Woodworth, TG, Abuelo, JG, Austin, HA III, Esparza, A. Severe glomerulonephritis with late emergence of classic Wegener's granulomatosis. Report of 4 cases and review of the literature. Medicine (Baltimore) 1987; 66:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/18\">",
"      Hauschild S, Schmitt WH, Csernok E, et al. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. Adv Exp Med Biol 1993; 336:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/19\">",
"      Tervaert JW, Kallenberg CG. Anti-myeloperoxidase antibodies in Churg-Strauss syndrome. J Neurol 1993; 240:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/20\">",
"      Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/21\">",
"      Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/22\">",
"      Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/23\">",
"      Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/24\">",
"      Sabl&eacute;-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/25\">",
"      Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990; 37:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/26\">",
"      Hellmark T, Niles JL, Collins AB, et al. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 1997; 8:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/27\">",
"      Weber MF, Andrassy K, Pullig O, et al. Antineutrophil-cytoplasmic antibodies and antiglomerular basement membrane antibodies in Goodpasture's syndrome and in Wegener's granulomatosis. J Am Soc Nephrol 1992; 2:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/28\">",
"      Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/29\">",
"      Yang G, Tang Z, Chen Y, et al. Antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with anti-GBM crescentic glomerulonephritis. Clin Nephrol 2005; 63:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/30\">",
"      Olson SW, Arbogast CB, Baker TP, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 2011; 22:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/31\">",
"      Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005; 46:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/32\">",
"      Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/33\">",
"      Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study. Arthritis Rheum 2005; 53:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/34\">",
"      Gaskin G, Thompson EM, Pusey CD. Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment. Nephrol Dial Transplant 1995; 10:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/35\">",
"      Nanke Y, Akama H, Terai C, Kamatani N. Rapidly progressive glomerulonephritis with D-penicillamine. Am J Med Sci 2000; 320:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/36\">",
"      Bienaim&eacute; F, Clerbaux G, Plaisier E, et al. D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am J Kidney Dis 2007; 50:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/37\">",
"      Feriozzi S, Muda AO, Gomes V, et al. Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis. Ren Fail 2000; 22:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/38\">",
"      Sakai N, Wada T, Shimizu M, et al. Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. Nephrol Dial Transplant 1999; 14:2774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/39\">",
"      Gunton JE, Stiel J, Clifton-Bligh P, et al. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000; 142:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/40\">",
"      Lam DC, Lindsay RH. Accumulation of 2-[14C]propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 1979; 28:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/41\">",
"      Lee E, Hirouchi M, Hosokawa M, et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 1988; 37:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/42\">",
"      Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM 1995; 88:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/43\">",
"      Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 1998; 105:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/44\">",
"      Culver B, Itkin A, Pischel K. Case report and review of minocycline-induced cutaneous polyarteritis nodosa. Arthritis Rheum 2005; 53:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/45\">",
"      Sethi S, Sahani M, Oei LS. ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. Am J Kidney Dis 2003; 42:E27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/46\">",
"      Dunphy J, Oliver M, Rands AL, et al. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 2000; 142:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/47\">",
"      Schaffer JV, Davidson DM, McNiff JM, Bolognia JL. Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 2001; 44:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/48\">",
"      Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999; 28:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/49\">",
"      Kitahara T, Hiromura K, Sugawara M, et al. A case of cimetidine-induced acute tubulointerstitial nephritis associated with antineutrophil cytoplasmic antibody. Am J Kidney Dis 1999; 33:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/50\">",
"      Terjung B, Spengler U, Sauerbruch T, Worman HJ. \"Atypical p-ANCA\" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/51\">",
"      Locht H, Skogh T, Wiik A. Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis. Ann Rheum Dis 2000; 59:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/52\">",
"      Zhao MH, Jayne DR, Ardiles LG, et al. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 1996; 89:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/53\">",
"      Lachenal F, Nkana K, Nove-Josserand R, et al. Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. Eur Respir J 2009; 34:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/54\">",
"      McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol 2011; 6:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/55\">",
"      Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol 2011; 30:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/56\">",
"      Chung C, Tumeh PC, Birnbaum R, et al. Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine. J Am Acad Dermatol 2011; 65:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/57\">",
"      Ullrich K, Koval R, Koval E, et al. Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine. J Clin Rheumatol 2011; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/58\">",
"      Bajema IM, Hagen EC. Evolving concepts about the role of antineutrophil cytoplasm autoantibodies in systemic vasculitides. Curr Opin Rheumatol 1999; 11:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/59\">",
"      Choi HK, Lamprecht P, Niles JL, et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000; 43:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/60\">",
"      Bauer A, Jabs WJ, S&uuml;fke S, et al. Vasculitic purpura with antineutrophil cytoplasmic antibody-positive acute renal failure in a patient with Streptococcus bovis case and Neisseria subflava bacteremia and subacute endocarditis. Clin Nephrol 2004; 62:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/61\">",
"      Trimarchi M, Gregorini G, Facchetti F, et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore) 2001; 80:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/62\">",
"      Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/63\">",
"      Hermann J, Demel U, St&uuml;nzner D, et al. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall. Ann Rheum Dis 2005; 64:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/64\">",
"      Fayaz A, Pirson Y, Cosyns JP, et al. Pauci-immune necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus. Clin Nephrol 2008; 69:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/65\">",
"      Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995; 123:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/66\">",
"      Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/67\">",
"      Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/68\">",
"      Kyndt X, Reumaux D, Bridoux F, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/69\">",
"      Russell KA, Fass DN, Specks U. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2001; 44:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/70\">",
"      Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/71\">",
"      Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/72\">",
"      Han WK, Choi HK, Roth RM, et al. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003; 63:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/28/9674/abstract/73\">",
"      Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3060 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9674=[""].join("\n");
var outline_f9_28_9674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunofluorescence patterns in vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunofluorescence patterns in non-vasculitic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Caution when interpreting positive immunofluorescence results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Enzyme-linked immunoassays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal-limited vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Churg-Strauss syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Anti-GBM antibody disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19762502\">",
"      Other concurrent glomerular diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Drug-induced ANCA-associated vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Propylthiouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hydralazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Minocycline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Drug-induced interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nonvasculitic rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Autoimmune gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265754241\">",
"      Cocaine and levamisole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Is a positive test result a \"true-positive\"?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Does a negative ANCA assay exclude a small vessel vasculitis (GPA, MPA, CSS, and renal-limited disease)?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Does a positive ANCA obviate the need for confirmation of the diagnosis by tissue biopsy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Does a rise in ANCA titers predict a disease flare?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Does a persistently negative ANCA assure disease quiescence?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Technical issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3060|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/51/39742\" title=\"picture 1A\">",
"      C ANCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/6/17518\" title=\"picture 1B\">",
"      P ANCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3060|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/29/35291\" title=\"table 1A\">",
"      ANCA accuracy in GN in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/4/35915\" title=\"table 1B\">",
"      ANCA accuracy in GN in elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/32/35339\" title=\"table 1C\">",
"      ANCA accuracy in GN in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_28_9675="DDx congenital torticollis";
var content_f9_28_9675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of congenital torticollis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Congenital muscular torticollis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postural torticollis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pterygium colli",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unilateral absence of sternocleidomastoid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Sternocleidomastoid cysts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cystic hygroma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Branchial cleft cyst",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Vertebral anomalies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       C1-C2 articular joint lesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hemivertebra",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Klippel-Feil syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arnold Chiari malformation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9675=[""].join("\n");
var outline_f9_28_9675=null;
var title_f9_28_9676="Diseases of myelin";
var content_f9_28_9676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diseases of myelin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dysmyelinating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenoleukodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metachromatic leukodystrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Krabbe's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alexander's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canavan van Bogaert disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelizaeus-Merzbacher disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenylketonuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Demyelinating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Autoimmune",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute disseminated encephalomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute hemorrhagic leukoencephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Progressive multifocal leukoencephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Toxic/metabolic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin B12 deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mercury intoxication (Minamata disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol/tobacco amblyopia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central pontine myelinolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Marchiafava-Bignami syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Binswanger's disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9676=[""].join("\n");
var outline_f9_28_9676=null;
var title_f9_28_9677="Treatment of candidemia";
var content_f9_28_9677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of candidemia and invasive candidiasis in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Condition or treatment group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary",
"       </td>",
"       <td class=\"subtitle2\">",
"        Alternative",
"       </td>",
"       <td class=\"subtitle2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Candidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Nonneutropenic adults",
"       </td>",
"       <td>",
"        Fluconazole 800 mg (12 mg/kg) oral* loading dose, then 400 mg (6 mg/kg) orally* daily or an echinocandin",
"        <sup>",
"         &bull;",
"        </sup>",
"        . For species-specific recommendations, see text.",
"       </td>",
"       <td>",
"        A lipid formulation of amphotericin B 3 to 5 mg/kg IV daily; or amphotericin B deoxycholate 0.5 to 1 mg/kg IV daily; or voriconazole 400 mg orally (or 6 mg/kg IV) twice daily for two doses, then 200 mg orally (or 3 mg/kg IV) twice daily",
"       </td>",
"       <td>",
"        Choose an echinocandin for moderately severe to severe illness and for patients with recent azole exposure. Transition to fluconazole after initial echinocandin is appropriate in many cases. Remove all intravascular catheters, if possible. Treat 14 days after first negative blood culture result and resolution of signs and symptoms associated with candidemia. Ophthalmic examination recommended for all patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Neutropenic patients",
"       </td>",
"       <td>",
"        An echinocandin",
"        <sup>",
"         &bull;",
"        </sup>",
"        or a lipid formulation of amphotericin B 3 to 5 mg/kg IV daily. For species-specific recommendations, see text.",
"       </td>",
"       <td>",
"        Fluconazole 800 mg (12 mg/kg) oral* loading dose, then 400 mg (6 mg/kg) orally* daily; or voriconazole 400 mg orally (or 6 mg/kg IV) twice daily for two doses then 200 mg orally (or 3 mg/kg IV) twice daily",
"       </td>",
"       <td>",
"        An echinocandin or a lipid formulation of amphotericin B is preferred for most patients. Fluconazole is recommended for patients without recent azole exposure and who are not critically ill. Voriconazole is recommended when additional coverage for molds is desired. Intravascular catheter removal is advised but is controversial.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Suspected candidiasis treated with empiric antifungal therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Nonneutropenic patients",
"       </td>",
"       <td>",
"        Treat as above for candidemia. An echinocandin or fluconazole is preferred.",
"       </td>",
"       <td>",
"        A lipid formulation of amphotericin B 3 to 5 mg/kg IV daily or amphotericin B deoxycholate 0.5 to 1 mg/kg IV daily",
"       </td>",
"       <td>",
"        For patients with moderately severe to severe illness and/or recent azole exposure, an echinocandin is preferred. The selection of appropriate patients should be based on clinical risk factors, serologic tests, and culture data. Duration of therapy is uncertain, but should be discontinued if cultures and/or serodiagnostic tests have negative results.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Neutropenic patients",
"       </td>",
"       <td>",
"        A lipid formulation of amphotericin B 3 to 5 mg/kg IV daily, caspofungin 70 mg IV loading dose, then 50 mg IV daily, or voriconazole 400 mg orally (or 6 mg/kg IV) twice daily for two doses then 200 mg orally (or 3 mg/kg IV) twice daily",
"       </td>",
"       <td>",
"        Fluconazole 800 mg (12 mg/kg) oral* loading dose, then 400 mg (6 mg/kg) orally* daily; or itraconazole 200 mg (3 mg/kg) orally* twice daily",
"       </td>",
"       <td>",
"        In most neutropenic patients, it is appropriate to initiate empiric antifungal therapy after four days of persistent fever despite antibiotics. Serodiagnostic tests and computed tomography imaging may be helpful. Do not use an azole in patients who received azole prophylaxis previously. (See topic reviews on treatment of neutropenic fever.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Echinocandin dosing in adults is as follows: anidulafungin, 200 mg IV loading dose, then 100 mg IV daily; caspofungin, 70 mg IV loading dose, then 50 mg IV daily; and micafungin, 100 mg IV daily.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infections Diseases Society of America. Clin Infect Dis 2009; 48:503. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9677=[""].join("\n");
var outline_f9_28_9677=null;
var title_f9_28_9678="JEB variants";
var content_f9_28_9678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genotypic and phenotypic variants of junctional epidermolysis bullosa (lucidolytic)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Inheritance",
"        </p>",
"        <p>",
"         Mutated gene",
"        </p>",
"        <p>",
"         Targeted gene product",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JEB, Herlitz",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          LAMA3",
"         </em>",
"         ,",
"         <em>",
"          LAMB3",
"         </em>",
"         ,",
"         <em>",
"          LAMC2",
"         </em>",
"        </p>",
"        <p>",
"         Laminin &alpha;3 chain of laminin-332",
"         <br/>",
"         Laminin &beta;3 chain of laminin-332",
"         <br/>",
"         Laminin &chi;2 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Profound mechanical fragility at birth with extensive generalized, recurrent, often persistent blistering, erosions, and&nbsp;crusting covering not only particularly exposed skin areas (like palms and soles) but most or almost all of the body surface",
"         </li>",
"         <li>",
"          Scarring alopecia, milia, onychodystrophy, and nail loss",
"         </li>",
"         <li>",
"          Pseudosyndactyly",
"         </li>",
"         <li>",
"          Exuberant (periorificial) granulation tissue",
"         </li>",
"         <li>",
"          Involvement of oral cavity (microstomia, ankyloglossia), teeth (enamel hypoplasia, excessive caries), gastrointestinal (protein losing enteropathy, diarrhea), respiratory, genitourinary tract, conjunctivae",
"         </li>",
"         <li>",
"          Anemia, growth retardation, delayed puberty, high lethality",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, non Herlitz, generalized",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL17A1",
"         </em>",
"         ,",
"         <em>",
"          LAMA3",
"         </em>",
"         ,",
"         <em>",
"          LAMB3",
"         </em>",
"         ,",
"         <em>",
"          LAMC2",
"         </em>",
"        </p>",
"        <p>",
"         Type XVII collagen",
"         <br/>",
"         Laminin &alpha;3 chain of laminin-332",
"         <br/>",
"         Laminin &beta;3 chain of laminin-332",
"         <br/>",
"         Laminin &chi;2 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Generalized blistering from birth, atrophic scarring, milia; \"male-pattern\" alopecia; nail dystrophy and loss",
"         </li>",
"         <li>",
"          Involvement of oral cavity and teeth (excessive caries, teeth loss, enamel hypoplasia), gastrointestinal, respiratory and genitourinary tract, conjunctivae",
"         </li>",
"         <li>",
"          Anemia, growth retardation, protein losing enteropathy,&nbsp;diarrhea",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, non Herlitz, localized",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          COL17A1",
"         </em>",
"        </p>",
"        <p>",
"         Type XVII collagen",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Localized disease of lesser extent and lesser severity, onset at birth; milia, nail dystrophy and loss",
"         </li>",
"         <li>",
"          Involvement of oral cavity and teeth (excessive caries, enamel hypoplasia)",
"         </li>",
"         <li>",
"          Extensive atrophic scarring, hair loss, anemia, impairments of growth and development, ocular abnormalities or alterations affecting gastrointestinal, genitourinary, respiratory tract mostly absent",
"          <sup>",
"           [1]",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB with pyloric atresia",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          ITGA6",
"         </em>",
"         ,",
"         <em>",
"          ITGB4",
"         </em>",
"        </p>",
"        <p>",
"         Integrin &alpha;6, Integrin &beta;4",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Gestational hydramnion",
"         </li>",
"         <li>",
"          Generalized and profound blistering from birth, occasionally age-associated amelioration; atrophic scarring; nail dystrophy and loss",
"         </li>",
"         <li>",
"          Association with aplasia cutis congenita",
"         </li>",
"         <li>",
"          Enamel hypoplasia",
"         </li>",
"         <li>",
"          Pyloric atresia",
"         </li>",
"         <li>",
"          Congenital genitourinary malformations",
"         </li>",
"         <li>",
"          Sporadically rudimentary ear anlage",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, inversa",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          LAMA3",
"         </em>",
"         ,",
"         <em>",
"          LAMB3",
"         </em>",
"         ,",
"         <em>",
"          LAMC2",
"         </em>",
"        </p>",
"        <p>",
"         Laminin &alpha;3 chain of laminin-332",
"         <br/>",
"         Laminin &beta;3 chain of laminin-332",
"         <br/>",
"         Laminin &chi;2 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Blistering predominantly located in intertringinous areas/sites, typically displaying an overall extent that exceeds that observed in patients with JEB-nH, localized",
"          <sup>",
"           [1]",
"          </sup>",
"         </li>",
"         <li>",
"          Atrophic scarring, milia, hypo-/hyperpigmentation, dystrophic (or absent) nails",
"         </li>",
"         <li>",
"          Moderate oral mucosal lesions; dental enamel hypoplasia, caries and gastrointestinal abnormalities to a lesser extent as compared to other JEB-nH variants",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        JEB, late onset (former progressiva)",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         ?",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Mild form of JEB developing in young adulthood or later",
"         </li>",
"         <li>",
"          Dystrophic (or absent) nails, dental enamel hypoplasia and caries to a lesser severity than JEB-nH",
"         </li>",
"         <li>",
"          Hyperhidrosis",
"         </li>",
"         <li>",
"          Absence of dermatoglyphs on fingers, palms, toes and soles",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Laryngo-onycho-cutaneous syndrome",
"        <sup>",
"         [2-5]",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Autosomal recessive",
"        </p>",
"        <p>",
"         <em>",
"          LAMA3A",
"         </em>",
"        </p>",
"        <p>",
"         Laminin &alpha;3 chain of laminin-332",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          High incidence in Punjab",
"         </li>",
"         <li>",
"          Minimal skin blistering, erosions",
"         </li>",
"         <li>",
"          Extensive aberrant production of granulation tissue with delayed healing, atrophic scarring",
"         </li>",
"         <li>",
"          Involvement of larynx (altered cry) at birth, skin (face, nuchal) and conjunctiva (granulomatous papules, symblepharon) in infancy",
"         </li>",
"         <li>",
"          Nail dystrophy and loss",
"         </li>",
"         <li>",
"          Enamel hypoplasia, caries",
"         </li>",
"         <li>",
"          High childhood mortality due to laryngeal, gastrointestinal, and urethral strictures",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931.",
"       </li>",
"       <li>",
"        Shabbir G, Hassan M, Kazmi A. Laryngo-onycho-cutaneous syndrome: A study of 22 cases. Biomedica 1986; 2:15.",
"       </li>",
"       <li>",
"        Ainsworth JR, Spencer AF, Dudgeon J, et al. Laryngeal and ocular granulation tissue formation in two Punjabi children: LOGIC syndrome. Eye (Lond) 1991; 5:717.",
"       </li>",
"       <li>",
"        Ainsworth JR, Shabbir G, Spencer AF, Cockburn F. Multisystem disorder of Punjabi children exhibiting spontaneous dermal and submucosal granulation tissue formation: LOGIC syndrome. Clin Dysmorphol 1992; 1:3.",
"       </li>",
"       <li>",
"        Phillips RJ, Atherton DJ, Gibbs ML, et al. Laryngo-onycho-cutaneous syndrome: An inherited epithelial defect. Arch Dis Child 1994; 70:319.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9678=[""].join("\n");
var outline_f9_28_9678=null;
var title_f9_28_9679="Tricuspid regurgitation subcostal echocardiogram";
var content_f9_28_9679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50740/subtrire_conv.mp4?title=Tricuspid+regurgitation+subcostal+echocardiogram\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal view from a 2-D echocardiograms shows significant dilatation of the hepatic veins as a result of significant tricuspid regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_28_9679=[""].join("\n");
var outline_f9_28_9679=null;
